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ABSTRACT

Background and Significance: Narcolepsy is a chronic neurological disorder. These patients
experience various psychiatric and physical comorbid diseases and mortality at an increased rate
compared to the general population.

Additionally, patients with narcolepsy experience

approximately a doubling of various annual healthcare related facility visits, transactions, and costs
comparatively. Narcolepsy with cataplexy is generally believed to be more prevalent than
narcolepsy without cataplexy. However, incidence and prevalence estimates of narcolepsy (with
or without cataplexy) vary widely with few large epidemiological studies conducted worldwide
and none in the U.S evaluating these proportions in both children and adults utilizing a large health
care claims database.
One of the main mechanisms underlying narcolepsy, the destruction of hypocretin neurons,
is not clear. Two of the more noted hypotheses for this pathology are autoimmune and infection
based triggers in allele carrier patients. These have been highlighted since narcolepsy diagnoses
increased following the late 2000s influenza vaccinations, especially across Europe. Specific
influenza and streptococcal infections have also been considered. Large U.S. healthcare claims
database investigations of the association between specific infections and development of
narcolepsy were not found in the published scientific literature. Our goals were to enhance the
knowledge regarding the epidemiology and possible infection triggers of narcolepsy.

The

information gained may aid in the overall understanding of the condition, the possible vulnerable
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populations, and lead to hypotheses regarding which subpopulations research should be focused
upon and those triggers that may be avoided or reduced in exposure.
Methods: The Truven Health MarketScan Commercial Dissertation Database (THMCDD) was
used to estimate prevalence and incidence of narcolepsy, with and without cataplexy, by age
groups, gender, and region among patients under age 66 with continuous enrollment for years
2008-2010. THMCDD contains health claims information for over 18 million people. Prevalence
was expressed as cases/100,000 persons. Average annual incidence (using varying criteria for
latency between the diagnostic tests, polysomnograph coupled with MSLT, and the diagnosis) was
expressed as new cases/100,000 persons/year. Subsequently, we conducted a case-control study
to assess the differences in respiratory infections between patients with incident narcolepsy
diagnosis and controls. Continuously enrolled patients under age 66 were included. Cases of
narcolepsy occurring from July 1, 2009 through December 31, 2010 were included based on two
diagnosis criteria (using varying criteria for latency between diagnosis and the diagnostic tests).
Non-narcolepsy controls were frequency matched on look-back time by assigning an index date
equal to a case diagnosis date. Occurrence of prior respiratory infections was compared between
cases and controls based on narcolepsy criteria and four different time periods pre-index date.
Infections were grouped into 9 types based on pathogen and clinical manifestation.
Results: From 2008 through 2010, there were 8,444,517 continuously enrolled patients and 6,703
diagnosed with narcolepsy (prevalence overall:79.4/100,000; without cataplexy:65.4/100,000;
with cataplexy: 14.0/100,000). Based on the 3 definitions of incidence, overall average annual
incidence was 7.67, 7.13, and 4.87/100,000 persons/year. Incidence for narcolepsy without
cataplexy was generally several times higher than narcolepsy with cataplexy. Prevalence and
incidence were approximately 50% greater for females compared to males across most age groups.

vii

Prevalence was highest among the 21-30 age group, with incidence highest among enrollees in
their early 20s and late teens. Regionally, the North Central U.S. had the highest prevalence and
incidence, while the West was the lowest. For the case-control study, Adjusted odds ratio (aOR)
increases were statistically significant for Group 5 (acute respiratory infections), Group 8 (other
pneumonias, bronchopneumonia, etc.) and Group 9 (influenzas) across various time periods preindex date and for both narcolepsy criteria. Overall, the most significant aORs were for acute
respiratory infections during the 3 to 15 months pre-index date for both narcolepsy diagnosis
criteria (aOR=1.73, 95% 1.52 to 1.98 and aOR=1.83, 95% CI 1.57 to 2.19). The aORs for acute
respiratory infections were approximately 50% greater among females than males.
Conclusion: We observed higher prevalence and incidence of narcolepsy compared to most
previous studies.

Females were associated with approximately 50% increased proportions

compared to males. We also found that the greatest prevalence and incidence of narcolepsy
occurred in patients in their early 20s, and those residing in the North Central region of the U.S.
Perhaps most striking was the observation of much greater proportions of narcolepsy without
cataplexy compared to narcolepsy with cataplexy. In the case-control assessment, we found
increased occurrences of acute respiratory infections, pneumonias, and influenza prior to incident
narcolepsy diagnosis, compared to controls. Generally, these rates appeared higher for females
than males and occurred for both narcolepsy diagnosis criteria. Additionally, these associations
were observed in the infection assessment periods 3 to 15 months and 6 to 18 months prior to
incident narcolepsy diagnosis. Increased awareness and early notification among healthcare
providers for signs and symptoms of narcolepsy is critical in helping this population of patients
manage this burdensome condition. Also, the identification of potential narcolepsy triggers by
certain infections may aid in the understanding of the disease.

viii

These findings may have

implications in the understanding of mechanisms and causation of other acute onset neurological
disorders. Our observations of consistently increased risk of incident narcolepsy related to recent
previous viral respiratory infections and the inconsistent results for bacterial infections require
additional study to confirm these findings.
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CHAPTER ONE
INTRODUCTION
Significance and Justification
Narcolepsy is a chronic neurological disorder characterized primarily by excessive daytime
sleepiness (EDS) and, in most cases, cataplexy.1-4

Narcolepsy patients experience various

psychiatric and physical comorbid diseases and mortality at an increased rate compared to the
general population.5-10

Additionally, patients with narcolepsy experience approximately a

doubling of various annual healthcare related facility visits, transactions, and costs comparatively.
These include physician visits (11.1 vs. 5.6 per year), outpatient services (7.0 vs 3.2 per year),
outpatient visits (2.8 vs. 1.4 per year), emergency room visits (0.34 vs. 0.17 per year), inpatient
admissions (0.15 vs. 0.08 per year), drug transactions (26.4 vs. 13.3 per year), and costs for both
services ($8,346 vs. $4,147 per year) and drugs ($3,356 vs. $1,114 per year).11
Narcolepsy with cataplexy (NT1) is considered to be more prevalent than narcolepsy
without cataplexy (NT2).1 However, incidence and prevalence estimates of narcolepsy (with or
without cataplexy) vary widely with few large epidemiological studies available.12-21 Limited
studies have been conducted in the U.S. and none were found assessing incidence and prevalence
in both children and adults based on a large health care claims database.18-20
Patients diagnosed with narcolepsy with cataplexy often present with low hypocretin 1
(orexin A) in cerebrospinal fluid (CSF).1;3 The mechanism associated with the destruction of
hypocretin neurons is not clear.1 Two of the more noted hypotheses for this pathology are
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autoimmune and infection based triggers in allele carrier patients.22;23 These have especially
gained traction after narcolepsy increases were observed following influenza vaccinations and
possible influenza and streptococcal infections.23

Large U.S. healthcare claims database

investigations of the association between specific infections and development of narcolepsy were
not found in the published scientific literature.
When treatment of narcolepsy is necessary, the main focus of treatment is symptom
control.24 The typical approach is to treat narcolepsy associated excessive daytime sleepiness
(EDS) with stimulants.25;26 When patients present with co-occurring cataplexy and parasomnias
(e.g. hypnagogic hallucinations and sleep paralysis), the general approach is to treat with
antidepressants.25-27 Unfortunately, narcolepsy is a chronic disease. Even though pharmaceutical
products have shown promise in treating the symptoms, narcolepsy is incurable. Therefore, the
understanding of the epidemiology and possible triggers of narcolepsy will help in the overall
understanding of the condition, the possible vulnerable populations, and lead to hypotheses
regarding which subpopulations research should be focused upon and those triggers that may be
avoided or reduced in exposure.
Specific Aims and Research Questions
The primary goal of this investigation was to contribute to the understanding of possible
respiratory infection triggers of narcolepsy. This is currently relevant considering the recent and
ongoing influenza outbreak across the U.S. The goal was to determine the risk for narcolepsy,
using two incidence criteria and infection time periods, while considering factors for age, gender,
and geographic locations using the Truven Health MarketScan Commercial Dissertation Database
(THMCDD) for the period 2008 to 2010. Patients with narcolepsy were compared to controls
based on respiratory infection exposure. The central hypothesis was that there are specific
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respiratory infections that are related to the diagnosis of narcolepsy. Additionally, understanding
the overall incidence and prevalence of narcolepsy is relevant. Therefore, an additional manuscript
was developed to assess the epidemiology of narcolepsy, with and without cataplexy, in the U.S.
Since the development of the prevalence and incidence study was critical in creating the overall
database and identifying subjects for the primary manuscript, it is presented first. The respiratory
infection and resultant narcolepsy manuscript is presented second. To examine the central
hypothesis and the epidemiology of narcolepsy in the U.S., the following specific aims and
research questions were assessed:
Aim 1: Determine whether specific respiratory infections are associated with development of
narcolepsy in the U.S.
•

Q1: Are patients with incident narcolepsy associated with increased diagnosis for
respiratory infections, prior to narcolepsy diagnosis, compared to controls?

•

Q2: Are there differences in risk based on narcolepsy diagnosis criteria, exposure time
periods, and gender?

Aim 2: Determine the incidence and prevalence of narcolepsy in the U.S.
•

Q1: What are the incidence and prevalence of narcolepsy, with and without cataplexy,
in the U.S.?

•

Q2: Do the incidence and prevalence of narcolepsy differ by age group, gender, and
geographical location?

3

Conceptual Framework
The following diagram, Figure 1.1, represents the conceptual framework for the
manuscripts that are the basis of this dissertation. The conceptual framework for the incidence
and prevalence manuscript and the related respiratory infections manuscript details the
relationships for known and unknown factors and the modification pathways that may exist. The
primary outcome for both manuscripts was narcolepsy diagnosis. The conceptual framework was
loosely based on the descriptions of methods of developing frameworks found in the publication
by Victora and colleagues.28
The known and unknown factors are noted by the colors of the boxes. The conceptual
frameworks for these studies are somewhat complicated and difficult to display pictorially.
However, even with the web of relationships/associations that occur among the factors, creating
the framework in figure format actually allows for an easier determination of which adjustments
and factors may or may not need to be taken into account when creating the statistical models.
Additionally the frameworks aid in the discussion of the study and results. The possible unknown
factor influences were addressed when discussing the limitations of the studies.
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Figure 1.1 Conceptual Framework for Incidence/Prevalence and Related Respiratory Infections Manuscripts
= Variables in Truven
= Information not available
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Infection, other
diagnosis
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Infection, other
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Review of Literature and Background
This review of narcolepsy-associated literature is focused on presenting information related
to the two manuscripts that will be the focus of this dissertation. Additionally, a brief overview of
the background and issues associated with using the Multiple Sleep Latency Test (MSLT) and
treatment will be provided.
Primarily, the available epidemiological studies evaluating the incidence and prevalence
of narcolepsy, comorbidities, associated vaccinations and infections, and drugs used to treat
narcolepsy will be discussed. All large population-based and health care claims database studies
were reviewed and relevant information will be provided. Additionally, any novel, smaller studies
investigating limited information topics, and systematic reviews or meta-analyses will be included.
With respect to drugs used to treat narcolepsy, since studies are limited, a discussion of standards
of care and use in the literature and any safety and efficacy information will be reviewed.
The review of literature was conducted for all articles related to narcolepsy using PubMed,
Embase, Scopus, Web of Science, Google Scholar, and Grey Literature. In order to obtain all
relevant articles, first, all fields were searched for the terms “narcolepsy”, “narcoleptic”, and
“narcolep*”. Additionally, “cataplexy”, “sleep paralysis”, and “hypnogogic hallucinations” were
included in the search. However, all literature references obtained with these searches were found
when searching for narcolepsy. “Multiple Sleep Latency Test” or “MSLT” was also searched via
all fields for background information and relevant articles obtained. The primary search was
conducted and updated monthly through the end of January 2018.
The searches for narcolepsy resulted in the following numbers of references (Google
Scholar will not be presented since it was used as a confirmatory source, and Grey Literature did
not provide any usable material):

6

•

PubMed – 4,988

•

Embase – 3,335

•

Scopus – 2,189

•

Web of Science – 2,296

After exclusion of duplicates and review of all titles and abstracts, 1,289 articles were
determined to be relevant to the dissertation topics. Therefore, all 1,289 articles were obtained.
After brief review of these articles and their cited references, another 144 publications were
obtained. This resulted in a total of 1,433 articles obtained from all sources.
A priori, it was determined that case reports, case series, and most conference and meeting
abstracts would not be included in the literature review (abstracts would be considered if the
information was determined to be extremely important). A review of about 10% of these abstracts
found that many were later published as full journal articles. Additionally, most abstracts did not
provide full results, methods, etc. After exclusion of these and full review of each article, 258
were considered for further review.
Finally, after exclusion of early/duplicative data and non-relevant publications, 162 articles
were included. Since January 2018, literature searches were conducted bi-weekly to determine if
any new relevant material was available or it was found that an article previously deemed
unobtainable could then be accessed. This led to the retrieval of an additional 32 articles. Also
cited is the FDA website from which pharmaceutical product information was obtained.
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Narcolepsy Background
Description and Biological Background
Narcolepsy is a chronic neurological disorder characterized primarily by excessive daytime
sleepiness (EDS) and, in most cases, cataplexy.1-4 Other symptoms may be experienced. These
are less common, but include hypnagogic hallucinations (hallucinations when falling asleep),
hypnopompic hallucinations (hallucinations upon waking), and sleep paralysis (inability to move
upon awakening).1;2;4 Cataplexy is characterized by one or more sudden short term (<2 minutes)
losses of muscle tone (often due to an emotional trigger), yet consciousness is retained.3
As of 2014, narcolepsy is categorized as narcolepsy type 1 (NT1) and narcolepsy type 2
(NT2).1;3 NT1, which describes most narcolepsy patients who also present with cataplexy, is
associated with an absence of hypocretin peptides.1;2;22 These peptides, also known as orexins,
help to regulate wakefulness and sleep.2 NT1 patients often present with low hypocretin 1 (orexin
A) in cerebrospinal fluid (CSF).3 Patients with NT2 (without cataplexy) present with normal or
slightly lower levels of orexin A in the CSF.1;29 These reclassifications are based on biomarkers,
not clinical presentation.29 Almost all NT1 patients develop cataplexy.1;29 However, some
narcolepsy patients with cataplexy have normal hypocretin CSF levels, suggesting other causative
factors.1;30 These patients are still identified as NT1.1 Therefore, for this review and throughout
this dissertation the description of “narcolepsy with cataplexy” and NT1 will be used
interchangeably.
Destruction of hypocretin producing neurons in the hypothalamus is associated with NT1.31
Additionally, NT1 patients are almost always HLA-DQB1*06:02 allele carriers.1;22;32 However,
other genetic variations have been identified, including but not limited to alleles HLADQB1*03:01, HLA-DPB1*05:01, and HLA-A*11:01.22;33 On the other hand, NT2 patients often
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have normal CSF hypocretin levels, or slight reductions.29;34 NT2 has been considered idiopathic
or possibly due to undiscovered genetic links.29
The mechanism associated with the destruction of hypocretin neurons is not clear. Two
of the more noted hypotheses for this pathology are autoimmune and infection based triggers in
allele carrier patients.22;23 These have especially gained traction following narcolepsy increases
observed following influenza vaccinations and certain infections.23 However, clear mechanisms
have still not been established.1
Diagnosis
The Multiple Sleep Latency Test (MSLT) is used for the diagnosing of narcolepsy and is
preferentially performed following a polysomnography (PSG).35;36 To conduct the MSLT, patients
attempt 4 to 5 20-minute naps. Each nap period begins approximately 2 hours after the previous
nap. During the test, EEG, heart rate or ECG, and eye and muscle activity are recorded. Sleepiness
is graded on how long the patient takes to show any signs of a stage of sleep. Categories of
sleepiness have been generally provided: severe (0-5 min.), troublesome (5-10 min.), manageable
(10-15 min.), and excellent (15-20 min.).35 Various researchers have made slight modifications to
the grading system over the years. However, diagnostic criteria for narcolepsy, with or without
cataplexy have been considered positive if mean sleep latency is ≤8 minutes.37-39 It has been noted
that MSLT should be used in conjunction with other criteria in order to obtain a diagnosis of
narcolepsy (e.g. two or more episodes of sleep-onset REM periods (SOREMPs) during the MSLT,
review of sleep diaries).39-46
Various factors have been noted to possibly impact the validity of MSLT for the diagnosis
of narcolepsy. These include temporality of assessment, sleep quality and disorders, circadian
phase, recent sleep issues, pharmaceuticals, ingestion of certain foods, patient age, technician skill,
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sleep apnea, and other psychological and physical conditions.21;39;40;42;45-51 However, despite these
concerns, the MSLT has been considered an accurate tool in the assessment of the ability to fall
asleep, has been validated, and has high test-retest reliability.42
Incidence and Prevalence of Narcolepsy
Narcolepsy, with or without cataplexy, is a rare disease with wide varying incidence and
prevalence estimates.1;12-16 Additionally, it has been noted that incidence and prevalence for
narcolepsy without cataplexy are difficult to obtain.17 Because of the concern for unreliable
estimates possibly generated from small studies of a rare condition, this review of the published
literature will primarily focus on large population-based epidemiological studies published during
the last decade. However, novel studies (i.e. first estimates of incidence) will be considered.
Studies providing estimates of incidence and prevalence of narcolepsy and, if available, the
associated symptoms of excessive daytime sleepiness (EDS), cataplexy, hypnagogic
hallucinations, and sleep paralysis will be included.
An overview of investigations of various co-occurring illnesses, other than those symptoms
typically associated with the disease (i.e. cataplexy, hypnagogic hallucinations, and sleep
paralysis) and other sleep disorders, will be also be provided. However, because the heightened
concern for risk of narcolepsy developed following the influenza pandemic during the 2008 to
2010 period, and the need for investigation of the narcolepsy-infection relationship, a focus will
be on infections and vaccinations related to incidence and prevalence. Therefore, the review of
other comorbid conditions will consider only larger epidemiological studies. The review of
incidence and prevalence will not be restricted to studies originating in the U.S., since information
is limited and any differences among populations may be of significance. Case reports and case
series are excluded.
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U.S.-Based Assessments of Risk
Possibly the earliest large-scale, population-based, study of both the incidence and
prevalence of narcolepsy was conducted in Olmsted County, MN.18 Using a records-linked system
and review of diagnosed narcolepsy medical records for patients diagnosed from 1960 to 1989. A
total of 72 cases were identified. The mean annual incidence of narcolepsy was 1.37/100,000
persons. The rate in men was higher than women (1.72 vs. 1.05 per 100,000 per year). Specifying
narcolepsy with cataplexy, the overall incidence was 0.74/100,000 per year. The rate was highest
among 10 to 19 year olds (3.84/100,000 per year). Narcolepsy prevalence in 1985 was calculated
as 56.3/100,000 persons, with the rate being higher in men than women (72.5 vs. 41.3). Narcolepsy
with cataplexy prevalence was 35.8/100,000 persons.
The prevalence of narcolepsy with cataplexy and DQB1*0602 allele status in adults was
studied in King County, Washington (U.S.) from 2001 to 2005.19 This registry attempted to obtain
interviews and buccal swabs from all patients with diagnoses of narcolepsy occurring prior to July
2001. Prevalence of narcolepsy was estimated to be 21.8 per 100,000 persons. Narcolepsy
prevalence in patients with positive DQB1*0602 allele status was estimated to be 15.3 per 100,000
persons. Both African-Americans and women were associated with increased risk for narcolepsy
compared to other races and men, respectively.
The incidence and prevalence of narcolepsy in U.S. military personnel was determined
using the Defense Medical Surveillance System (DMSS).20 Following exclusions, included were
1,675 cases determined to be incident (criteria: 2 narcolepsy diagnoses within 6 months with at
least 1 diagnosis by a sleep physician, or MSLT/polysomnography followed by narcolepsy
diagnosis, or 2 narcolepsy diagnoses within 6 months by any physician and a prescription for a
narcolepsy medication within 14 days of diagnosis). From 2004 through June 2013, annual
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incidence rates ranged from 14.6/100,000 person-years to 27.3/100,000 person-years for ages 18
years and above. Rates generally increased through the time period. Incidence rates were higher
in personnel ≥25 years of age compared to those aged 18 to 24 years for every annual period other
than 2007 to 2008. Incidence rates were 50 to 100% greater in women, compared to men, for most
years. Multivariate logistic regression showed that risk was greatest for the Midwest region
(OR=1.15, 95% CI 0.98-1.34) and among non-Hispanic black personnel (OR=1.52, 95% CI 1.351.71).
Foreign-Based Assessments of Risk
Ohayon and colleagues conducted the first large-scale estimation of the prevalence of
narcolepsy in the general European population.52

Using five countries (United Kingdom,

Germany, Italy, Portugal, and Spain) with a population of over 200 million people, a random
sample of 18,980 subjects were interviewed using the Sleep-EVAL expert system. Prevalence was
estimated to be 47/100,000 persons, with severe narcolepsy being 26/100,000 persons and
moderate being 21/100,000 persons.
Using the Ullanlinna Narcolepsy Scale (UNS), a random survey was conducted of 14,548
Norwegian citizens 20 to 60 year of age to assess prevalence of narcolepsy with cataplexy.53
Follow-up of respondents (61.8%) using telephone interviews and clinical evaluations found the
prevalence of narcolepsy with cataplexy to be 0.022% (95% CI 0.006-0.08%). This estimate may
be influenced by the lack of previously diagnosed narcolepsy in the responders.
The prevalence of narcolepsy with cataplexy was studied in Korean adolescents using the
UNS.54 A total of 20,407 students aged 14-19 years were interviewed and suspected cases of
narcolepsy were confirmed via MSLT and HLA. Prevalence was estimated to be 15/100,000
persons.
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A multi-national European (Denmark, Finland, Italy, the Netherlands, Sweden, and U.K)
linked healthcare database was used to assess narcolepsy incidence by country and age groups for
the 2000 to 2010 time period.55 Pooled incidence for the entire population was 0.93/100,000
person years (95% CI 0.90 to 0.97). Italy had the lowest rate (0.27/100,000 person years), while
Denmark had the highest rate (1.42/100,000 person years). The highest observed pooled incidence
rate by age group was among those 20 to 59 years of age (1.06/100,000 person years). The highest
incidence for a specific group during the time period was for Finnish 5 to 19 year olds
(2.12/100,000 person years). The lowest pooled incidence was in children under five years of age
(0.13/100,000 person years; 95% CI 0.07 to 0.20). This age group was also associated with the
lowest incidence for each specific country compared to the other age groups. Incidence rates
increased in certain groups following the influenza pandemic (discussed later in this review).
Family, Racial, and Environmental Issues
Increased risk for narcolepsy has been suspected among family members of diagnosed
narcoleptics.14;56 A Hong Kong-based study found that the prevalence for narcolepsy, assessed
via PSG and MSLT, among first degree family members was 12.3%, an approximate 200-fold
increased risk compared to the general population.57
Little is known about epidemiological racial/ethnic differences in narcolepsy, with smaller
studies providing wide ranges in estimates (e.g. Japanese prevalence: 0.59%; Israeli Jews:
0.00023%).17;58-61 Ethnic differences have been suggested to be attributed to study designs.58;62
Use of interviews coupled with diagnostic tests, such as MSLT, may actually show fewer
differences among races/ethnicities.62 A Chinese study of 9,851 interviewed adult subjects,
followed by possible cases assessed via HLA and MSLT, found the prevalence to be 34/100,000
persons.58 The investigators noted that this rate is similar to previous studies with more rigorous
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epidemiological methods. Prevalence (26/100,000 persons) obtained from the Finnish Twin
Cohort was considered similar to other races and ethnicities.62
Kawai and colleagues studied narcolepsy patients from 1992 to 2013 and found that MSLT,
PSG, and sex ratios were similar among African-Americans (n=182), Asians (n=35), Latinos
(n=41), and Caucasians (n=839) with narcolepsy.

However, among the groups, African-

Americans had earlier onset age and a greater ESS score. Additionally, African-Americans were
associated with higher HLA-DQB1*06:02 positivity (91.0% vs 65.0-80.0%), frequently low CSF
hypocretin-1 level (93.9% vs 61.5-85.7%), and 3.5 times more frequently without cataplexy
compared to Caucasians.17
Environmental toxins have been theorized to be associated with increased risk for
narcolepsy.63 Ton and colleagues conducted a case-control study, in King County Washington,
U.S., of DQB1*06:02 allele-positive adults to determine risks of exposures occurring before 21
years of age. Heavy metals (OR=4.7), high levels of woodwork (OR=3.0), fertilizer (OR=3.1),
and weed/bug killer (OR=4.5) were associated with statistically significant increases in risk. In
the genetically susceptible population, environmental exposures have been hypothesized to trigger
narcolepsy development.64
Incidence, Prevalence, and Risk Related to Vaccinations, Pandemics, and Infections
The association of vaccination and narcolepsy has been studied in large population-based
investigations. Some of these studies have found an increased risk for narcolepsy when comparing
pre- and post-vaccination efforts or when comparing vaccinated to non-vaccinated groups. The
studies have primarily been conducted to assess the risk in populations vaccinated against
influenza.
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Foreign Studies Observing Increased Risk with Influenza Vaccine
Using the Finnish Population Information System database, vaccinations and records of all
children in Finland under the age of 19 were analyzed in those born between 1991 and 2005, with
specific follow-up in 2009 and 2010 (pre-media notoriety).65 Narcolepsy incidence, via Poison
regression, was 9/100,000 person-years in the vaccinated (Pandemrix vaccine) group and
0.7/100,000 person-years in the unvaccinated group. The rate ratio was 12.7 (95% CI 6.1 to 30.8).
The attributable risk due to vaccination was 1/16,000 doses (95% CI 1/13,000 to 1/21,000).
Sensitivity analyses using varying follow-up times revealed statistically significant increases in
narcolepsy risk for all periods.
In another study of the Finnish population, the change in narcolepsy incidence following
H1N1 vaccination from 2002 to 2010 in the National Hospital Discharge Registry was evaluated.66
From 2002 to 2009 the annual incidence in children was 0.31/100,000 persons. In 2010 alone, the
incidence rose to 5.3/100,000 persons (total n=54). Of the 34 children that were HLA-typed, all
were positive for the DQB1*0602/DRB1*15 allele. The 2010 incidence in adults was similar to
the 2002 to 2009 time period. The Pandemrix vaccine was considered the contributory factor for
the increase in pediatric incidence.
The pediatric incidences of narcolepsy in western Sweden were evaluated during the period
beginning January 2000 and ending December 2010.67 Identified in pediatric hospitals, clinics,
and rehabilitation center, 28 children were diagnosed with narcolepsy following mass Pandemrix
vaccination, while 9 children were diagnosed prior to the vaccination campaign. Those diagnosed
after the vaccinations were associated with median time-to-symptom of 9.5 weeks and median
onset-to-diagnosis of 1-year. Prior to vaccinations in October 2009, the incidence of narcolepsy
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in children was 0.2/100,000 (95% CI 0.12 to 0.5) persons per year. Following vaccinations, the
incidence climbed to 6.6/100,000 (95% CI 3.4 to 8.1) persons per year. This difference in incidence
was highly significant (p<0.000001).
In a follow-up national registry-based cohort study of 3,347,467 Pandemrix-vaccinated and
2,497,547 unvaccinated individuals from 2009 to 2011 in Sweden, the risk for neurological
diseases was assessed.68 Narcolepsy was associated with the greatest statistically significant
increased risk (HR=2.92, 95% CI 1.78 to 4.79) following vaccination in persons 20 years old and
younger. This equated to an attributable excess incidence of 4/100,000 vaccinated children per
year. Individuals 21 to 30 years of age were also associated with increased risk for narcolepsy
following vaccination (HR=2.18, 95% CI 1.0 to 4.75). Risks were not different when comparing
the first and second years following vaccination.
Following the reports of increased narcolepsy after Pandemrix vaccination in Finland and
Sweden, Miller and colleagues conducted a case-control study to determine the possible risk of
narcolepsy following the same vaccinations in the U.K.69 Narcolepsy diagnosed since 2008 in
children 4 to 18 years of age from British sleep centers and vaccination information from the
General Practitioner’s Database were obtained. Narcolepsy was identified in 75 cases and the risk
for narcolepsy overall (OR=14.4, 95% CI 4.3 to 48.5) was elevated along with risk of narcolepsy
within 6 months of vaccination (OR=16.2, 95% CI 3.1 to 84.5). Attributable risk was 1/57,500 to
1/52,000 doses. The relationship was considered causal. However, the researchers cautioned
against overestimation of this risk due to referral bias because of recent notoriety.
Another study assessing the risk for narcolepsy in adult patients exposed to the Pandemrix
vaccine was conducted in 6 English sleep centers from November 2012 to February 2014.70 Forty
cases were included in this case-coverage design. Five patients were exposed to Pandemrix
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vaccination within 3 to 18 months prior to narcolepsy with cataplexy onset. Compared to
population-based controls (using the Clinical Practice Research Datalink), elevated risk associated
with vaccination was observed in patients diagnosed prior December 2011 (pre-notoriety)
(OR=9.06, 95% CI 1.90 to 43.17). Risk of narcolepsy after vaccination was also elevated when
considering anytime of diagnosis (OR=4.24, 95% CI 1.45to 12.38). The attributable risk was
0.59/100,000 vaccinations.
A multi-national European (Denmark, Finland, Italy, the Netherlands, Sweden, and U.K)
linked healthcare database was used to assess narcolepsy incidence pre and post influenza
vaccination time periods.55 Review of data from 2000 through 2010 revealed increased incidence
rates post-vaccination compared to the pre-vaccination period. Statistically significant increased
risks for narcolepsy with influenza vaccination were observed for the 5 to 19 year age group in
Denmark (RR=1.9, 95% CI 1.1 to 3.1), Finland (RR=6.4, 95% CI 4.2 to 9.7), and Sweden (RR=7.5,
95% CI 5.2 to 10.7). Patients over 60 years of age were associated with increased risk postvaccination in Finland (RR=1.9 95% CI 1.1 to 3.3). A significant increase in risk post-vaccination
was also observed among 20 to 59 year olds in Denmark (RR=1.5, 95% CI 1.2 to 1.9).
Interestingly, a decrease in this age group was witnessed in the U.K. (RR=0.41, 95% CI 0.22 to
0.74).
The risk of narcolepsy in children and young adults following influenza vaccination was
investigated in Norway.71 Residents 3 to 29 years of age (n=1,638,526) were followed from 2008
through 2012. The risk of narcolepsy within 6 months following influenza vaccination with
Pandemrix was highly significant (adjusted HR=17.21, 95% CI 6.28 to 47.14) based on Cox
proportional-hazards regression. Risk was also elevated within 1 year after vaccination (HR=8.71,
95% CI 4.03 to 18.82) and through the end of follow-up (HR=5.53, 95% CI 3.01 to 10.15).
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H1N1 vaccination and narcolepsy were investigated in two large clinic and reimbursement
databases in Ireland, spanning the period April 2009 to December 2010.72 Cohorts consisted of
ages 5-19, and >19. Besides the primary analysis, the period was divided in pre and post public
notoriety of the possible link between vaccination and narcolepsy.

Vaccination with the

Pandemrix influenza vaccine was associate with pediatric incidence of 5.7/100,000 (95% CI 3.4
to 8.9) compared to 0.4/100,000 (95% CI 0.1 to 1.0) in unvaccinated children. The relative risk
was 13.9 (95% CI 5.2 to 37.2), with absolute attributable risk equal to 5.3/100,000 (95% CI 3.8 to
6.8) vaccinated children. The number of adult narcolepsy cases was too few for meaningful
evaluation.
Incidence rates of narcolepsy in Germany were investigated before, during, and after the
2009 influenza pandemic.73 Included were 1,198 patients from 233 sleep centers. Pediatric
incidence rates rose from 0.14/100,000 person-years (pre-pandemic/pre-vaccination) to
0.50/100,000 person-years (post-pandemic/post-vaccination). Incidence in adults remained stable
(0.56 to 0.67/100,000 person-years).
A subsequent case-control study of narcolepsy, vaccinations, and infections was also
conducted in Germany by Oberle and colleagues.74 Narcolepsy cases (n=103) diagnosed from
2009 to 2012 via MSLT were matched to population-based controls (n=264) and compared to
individuals (n=29) who tested negative on the MSLT. Narcolepsy risk was associated with
influenza vaccination (Pandemrix) when compared to population controls (adjusted OR=4.5, 95%
CI 2.0 to 9.9). When compared to test-negative controls, the increased OR was not significant
(adjusted OR=1.8, 95% CI 0.3 to 10.1). No other vaccinations were associated with development
of narcolepsy. The findings related to infections will briefly be discussed in the subsequent section
of this review. This increased risk for narcolepsy in Germany, related to vaccination with

18

Pandemrix, was also observed by this same research group in an evaluation of spontaneously
reported cases reported to the Paul-Ehrlich-Institut.75 Post wide-spread vaccination through 2016,
narcolepsy within 4 months of vaccination was observed 3.8-fold (95% CI 2.6 to 5.4) greater than
expected. Six months following vaccination, narcolepsy was diagnosed 2.8-fold (95% CI 2.0 to
3.9) higher than expected. The risk was even greater in the pediatric population: 15-fold (95% CI
8.7 to 24.0) higher within 4 months and 11.7-fold (95% CI 7.2 to 18.1) higher within 6 months.
H1N1 ASO3-adjuvanted and non-adjuvanted vaccine-associated MSLT-confirmed
narcolepsy with cataplexy was investigated in a French case-control study.76 This multicenter
study found that H1N1 vaccination (Pandemrix and Panenza) was strongly associated with a
statistically significant increase in narcolepsy for adults (OR=4.7), children (OR=6.5), and overall
(OR=5.5). Diagnoses after July 2010 was associated with a much greater risk (OR=7.6) compared
to diagnoses received prior to July 2010 (OR=2.8). H1N1 vaccination was the only variable
associated with risk for narcolepsy.
Review of data from the Norwegian National Institute of Public Health revealed
statistically significant (p<0.0001) increase in incidence of narcolepsy with cataplexy in patients
aged 4 to 19 years after the 2009 to 2010 influenza Pandemrix vaccinations.77 Forty two of the 48
cases had symptom onset within 6 months of vaccination. Within the first year after vaccination,
incidence rose to 10/100,000 persons per year (approximately 10 times greater than expected).
A retrospective study of sleep-center, neurologist, and lung specialist referred narcolepsy
patients and matched population and immunization registry controls was conducted in Quebec,
Canada using cohort, self-controlled case series, and case-control methodologies.78

Cases

(confirmed via MSLT) and controls were compared on influenza vaccination (Arepanrix) status
for the period 2009 to 2011. Overall incidence was calculated as 1.5/million person-years. The
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risk was increased for narcolepsy within 16 weeks following vaccination (Poisson RR=4.32, 95%
CI 1.50 to 11.12). However, the elevated risk was not statistically significant when assessed using
the case-series (RR=2.07, 95% CI 0.70 to 6.17) or case-control (OR=1.48, 95% CI 0.37 to 7.03)
methods. The attributable risk was approximately 1/million vaccine doses. The effects of
confounding by influenza infection on this small increase could not be ruled-out and the risk
appeared greater during the period of the pandemic.
Studies Not Observing Increased Risk with Influenza Vaccine
Other large population-based studies have not revealed a change in incidence rates of
narcolepsy prior to, during, or post-influenza outbreaks and vaccination campaigns.
Using the Kaiser Permanente Northern California health plan data, 2 to 49 year old
individuals vaccinated (quadrivalent live attenuated influenza) in 2013 to 2014 were compared to
unvaccinated subjects and followed for various outcomes, including development of narcolepsy.79
Exposed (n=62,040), unexposed (n=61,803), and active controls (inactivated influenza vaccine,
n=57,185) were matched on age and followed for up to 1 year. Incidence rates of narcolepsy were
similar among the groups.
Since signals for increased risk of narcolepsy were not found in the FDA Vaccine Adverse
Event Reporting System, researchers from the U.S. CDC assessed the Vaccine Safety Datalink
database for records between 2006 and 2011 (vaccine data from CDC and several healthcare
organization).80 Available medical records were reviewed. Of the 8.5 million yearly population,
patients under 30 years of age receiving the pandemic (2009) and seasonal influenza (2010-2011)
vaccinations were included. Of the over 1.5 million vaccinated, no cases of narcolepsy were
recorded within 6 months of vaccination and only 2 cases occurred after the 2010 to 2011 period.
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Vaccination with the A(H1N1)pdm09 strain was not associated with risk of narcolepsy. The
authors noted that the Pandemrix vaccine (GSK) was not distributed in the U.S.
A South Korean ecological study of data from 2007 to 2010 observed similar incidence
rates pre and post-influenza vaccination.81 Data from the Health Insurance Review Agency and
Korea Centers for Disease Control and Prevention, covering more than 97% of the population, in
fact revealed that pediatric narcolepsy incidence rates only ranged from 1.32 to 2.65 cases per
100,000 person-years.
Another study in South Korea analyzed the incidence of narcolepsy across the entire South
Korean Army before and after the 2009 H1N1 vaccination campaign using the MF59-adjuvanted
vaccine (623,771 of 750,000 soldiers, 83.2%).82 Suspected cases of narcolepsy from 2007 to 2013
were reviewed from all military hospitals. Forty one cases were definitive. Incidence rates of
narcolepsy pre-vaccination were similar to post-vaccination rates, with mean incidence of
0.91/100,000 persons per year.
In retrospect, it appears that the Pandemrix vaccine (and the Arepanrix vaccine to a lesser
extent) induced an increase in narcolepsy, as evidenced in those mass populations receiving the
vaccination. Comparatively, global areas not using these specific vaccinations did not observe
overall increases in subsequent narcolepsy diagnoses. A meta-analysis of studies reporting
incidence rates of narcolepsy following H1N1 influenza vaccination, conducted by Sarkanen and
colleagues, supports this conclusion.83 Eleven studies were included in the quantitative analysis.
Within 1 year following Pandemrix vaccination, risk of narcolepsy was increased in both the
pediatric (RR range=5.02 to 14.32, depending on diagnosis method) and adult (RR range=2.95 to
8.08, depending on diagnosis method) populations. Across the studies, the attributable risk in
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pediatric patients was approximately 5.4/100,000 vaccinations. Other vaccines used against
influenza did not show a clear increase in risk.
Interestingly, albeit using a small sample size (n=37), a recent study provided data
supporting the pathological association between Pandemrix vaccination and narcolepsy.84 These
researchers observed differences in expression of microRNA (miRNA) in narcoleptic patients and
in those receiving the Pandemrix vaccination. These miRNA differences have previously been
implicated in neurological diseases.85-87 Research has shown an increase in autoimmunity against
monosialodihexosyl-ganglioside (GM3), a human brain ganglioside, in patients vaccinated with
Pandemrix.88 Additionally, another investigation using proteomic and immunological approaches,
has suggested that Pandemrix is an antigen-specific narcolepsy inducer.89
Specific Infections
The limited epidemiological investigations into the association of infections and
narcolepsy have mainly been focused on streptococcal and influenza infections.90;91

Some

attempts have lacked statistical power to determine any relationship between narcolepsy and these
two categories of infection, 92 while others have been more promising. It has been noted that even
though serological evidence for a specific narcolepsy-associated infection such as influenza may
be weak, an inflammatory mechanism triggering autoimmunity may exist.93
In an assessment of factors for development of narcolepsy (n=162) from 2003 to 2012 in a
hospital-setting in Eastern China, Wu and colleagues observed that of approximately 40% of
patients with precipitating conditions within 6 months of diagnosis, about 63% included histories
of infections.94
In an evaluation of more specific infections, a case-control study was conducted of the
associations of Streptococcus pyogenes and Helicobacter pylori with development of narcolepsy
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in 200 cases and 200 controls.95 Streptococcus infection, and not Helicobacter, was associated
with narcolepsy. This association was observed for infections occurring within 3 years of
narcolepsy development.
Medical exposures in 45 U.S. (King County, Washington) narcolepsy patients, 18 to 50
years of age, were compared to 95 controls to determine possible triggers for the disease. All were
DQB1*0602 allele-positive.96 Adjusting for African-American race and lower income, strep
throat by age 21 (OR=5.4) and history of night terrors (OR=16.3) were the only conditions
associated with narcolepsy with cataplexy. The elevated OR (17.9) for arthritis was determined
to be an artifact due to limited population and history.
Influenza
It appears that most large epidemiologic studies regarding infection and narcolepsy have
investigated the risks related to influenza. This has especially been of interest since the European
outbreaks following the 2009-2010 pandemic.
Han and colleagues studied narcolepsy patients diagnosed from 1998 to 2010 in Beijing,
China.97 Incidence of narcolepsy was significantly increased following the H1N1 influenza
pandemic and was more than 3 times the expected rate of occurrence. This increase was
independent of vaccination, since only 5.6% of incident narcolepsy cases received vaccination and
occurred within 6 months of the pandemic. This same research group assessed the incidence of
narcolepsy in children 2 years after the 2009 H1N1 influenza pandemic.98 Data from 2011 and
2012 reveal that incident cases of narcolepsy were similar in numbers as those prior to the 2009
pandemic (5 to 6 times fewer than 2010). Additionally most symptoms, including, EDS, cataplexy,
sleep paralysis, and hypnagogic hallucinations were similar to the earlier years.
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A case-control study of narcolepsy, vaccinations, and infections was conducted in
Germany by Oberle and colleagues (previously discussed).74 Narcolepsy cases (n=103) diagnosed
from 2009 to 2012 via MSLT were matched to population-based controls (n=264) and compared
to individuals (n=29) who tested negative on the MSLT. Risk for narcolepsy was not associated
with any infections, including influenza.
The risk of narcolepsy in children and young adults following influenza infection was
investigated in Norway (discussed earlier).71 Residents 3 to 29 years of age (n=1,638,526) were
followed from 2008 through 2012. The risk of narcolepsy within 6 months following influenza
infection was elevated (adjusted HR=3.31, 95% CI 1.01 to 10.79). Non-significant elevated risks
were observed 1 year after infection (HR=2.36, 95% CI 0.73 to 7.61) and through the end of
follow-up after influenza infection (HR=1.67, 95% CI 0.68 to 4.12).
In a case-control study from a U.S.-based sleep center, 63 narcolepsy patients were
compared to 63 community control participants regarding possible environmental factor influences
on narcolepsy risk.99 Based on a questionnaire, the only infections presenting increased risk were
influenza within a year of onset (OR=1.79, 95% CI 1.05 to 3.04; Wald ꭓ2=4.61, p<0.05) and
unexplained fevers (OR=3.89, 95% CI 0.88 to 17.21; Wald ꭓ2=3.22, p<0.05).
Comorbidities Assessed in Observational Studies
Comorbidity studies have been conducted in patients with narcolepsy. These studies have
assessed various conditions and comparisons to general population controls, and others, have been
presented. This review will present recent major findings from large population-based and health
care claims observational studies. Comorbidities that are considered symptoms of narcolepsy (e.g.
cataplexy, EDS, sleep paralysis, hypnogogic hallucinations) or other sleep disorders will be
excluded.
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Jennum and colleagues conducted an evaluation of the Danish National Patient Registry
for comorbidities occurring before and after the first diagnosis (diagnosed from 1998 to 2012,
follow-up to 2014) of narcolepsy in children 0 to 19 years of age.5 For the 243 pediatric patients
with a narcolepsy diagnosis, compared to 970 randomly matched controls, elevated ORs were
observed prior to and after narcolepsy diagnosis for endocrine and metabolic conditions, nervous
disorders, psychiatric illnesses, pulmonary diseases, and other diseases. Prior to narcolepsy
diagnosis, ORs were elevated for congenital abnormalities, respiratory, and eye diseases.
Narcolepsy subjects were more at risk for injuries after their diagnosis, compared to controls.
Overall, patients with narcolepsy were associated with increased occurrence of comorbidities.
Using similar methods, the same investigators from Denmark assessed narcolepsy
comorbidities in 1,174 middle-aged (20-59 years of age) and 339 elderly (60+ years of age)
patients from 1998 to 2014.6 Cases were compared to controls 1:4. For both age groups,
narcolepsy patients were associated with greater ORs for diseases such as infections, neoplasms,
endocrine and metabolic, diabetes, psychiatric, neurological, eye, cardiovascular, respiratory,
gastrointestinal, musculoskeletal, and skin. Additionally, elderly narcoleptics had increased rates
of mortality compared to controls.
The largest assessment of comorbidities among U.S. narcolepsy patients was conducted
using the Truven Health Analytics MarketScan Research Databases.7 During the period 2006 to
2010, adult narcolepsy patients (n=9,312) were compared to controls (n=46,559) for prevalence of
comorbid conditions. Comorbidities were grouped by ICD-9 code using Clinical Classification
Software (CCS). Narcolepsy was associated with an increase for almost all comorbid groups, with
gender rates being similar. The largest excess prevalence was observed for mental illness (31.1%;
OR=3.8, 95% CI 3.6 to 4.0), digestive system diseases (21.4%; OR=2.7, 95% CI 2.5 to 2.8), and
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nervous system/sensory organs (20.7%; OR=3.7, 95% CI 3.4 to 3.9). Infectious and parasitic
diseases were associated with a 14.1% excess prevalence (OR=1.9 95% CI 1.8 to 2.0). Specific
infections were not elucidated.
Extending the investigation of the Truven database, psychiatric comorbidities were
assessed among narcolepsy patients.8 Increased prevalence in narcolepsy patients was observed
for mood disorders (37.9%, OR=4.0, 95% CI 3.8 to 4.2), depressive disorders (35.8%, OR=3.9,
95% CI 3.7 to 4.1), and anxiety disorders (25.1%, OR=2.5, 95% CI 2.4 to 2.7).
Another U.S.-based study surveyed 320 narcolepsy patients and 1,464 matched controls
for prevalence of comorbid conditions.9

Prevalence was increased among narcoleptics for

digestive disorders (OR=3.27, 95% CI 2.34 to 4.56), upper respiratory tract diseases (OR=2.52,
95% CI 2.00 to 3.17), heart diseases (OR=2.07, 95% CI 1.22 to 3.51), hypercholesterolemia
(OR=1.51, 95% CI 1.04 to 2.19), and hypertension (OR=1.32, 95% CI 1.02 to 1.70). Ten of the
12 individual psychiatric disorders assessed occurred statistically more frequently in narcoleptics,
except for alcohol dependence and dysthymic disorder.
This same study group also performed an evaluation of mortality related to narcolepsy in
the Symphony Health Solutions database.10 From 2002 to 2012, patients with at least one claim
for narcolepsy had an overall mortality rate approximately 1.5 times greater than those without
narcolepsy. Increased mortality rate was observed across all ages and genders, with males having
a higher standardized mortality ratio compared to females.
The comorbidity of autoimmune diseases and immunopathological disorders with
narcolepsy and cataplexy (type 1) was assessed in a case-control study in Spain.100 The group of
autoimmune diseases was increased in narcolepsy patients compared to controls (OR=3.17, 95%
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CI 1.01 to 10.07). The elevated risk was not statistically significant for immunopathological
disorders associated with narcolepsy.
In an evaluation of the possible increased risk of cancer in narcolepsy patients, the Taiwan
Longitudinal Health Insurance Database, covering 23 million people, was reviewed for data
reflective of 2000 to 2009.101 Comorbidities included in the Charleston comorbidity index were
considered for analysis.

Adult narcolepsy patients (n=2,833) were associated with overall

increased cancer risk compared to controls. Standardized incidence ratios based on Poisson
distribution were elevated for the overall population (SIR=1.32, 95% CI 1.04 to 1.66), females
(SIR= 1.52, 95% CI 1.05 to 2.13), female head and neck cancers (SIR=6.17, 95% CI 1.66 to 15.80)
and female gastric cancers (SIR=4.87, 95% CI 1.31 to 12.48). Males were not associated with
increased SIR overall or for specific cancers.
Olfactory disorder has been investigated among French and Italian narcolepsy patients.102
Compared to controls, olfactory dysfunction was significantly increased for narcoleptics
(OR=1.93, 95% CI 1.01 to 3.66). Olfactory dysfunction was also significantly increased in
narcolepsy patients with and without cataplexy in a study conducted at a sleep center in the Czech
Republic.103
Vitamin D deficiency has also been hypothesized to be associated with narcolepsy.104 A
study of serum levels of Vitamin D in patients with narcolepsy and cataplexy found an increased
frequency of vitamin D deficiency in these patients compared to controls (p<0.0238). However,
recently a larger case-control study of adult patients with narcolepsy and cataplexy (type 1)
(n=174) and vitamin D levels did not find a difference between cases and controls, after controlling
for clinical and demographic variables.105
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Obesity has been specifically linked to narcolepsy, especially considering the perturbations
on neuropeptides located in hypocretin neurons and the possible increase in body weight associated
with many of the drugs used to treat the condition.106;107 Dahmen and colleagues found an increase
in BMI in 132 patients with narcolepsy compared to general and psychiatric controls.108 These
same researchers found that BMI increases associated with narcolepsy were not related to eating
disorder.109 Interestingly, a case-control study of narcoleptics (n=60) and matched controls found
an increase in prevalence of eating disorders among narcoleptics.110 Yet, a longitudinal study of
pediatric narcolepsy patients found that even though BMI increased in patients soon after
narcolepsy with cataplexy onset, increase in BMI gradually subsided over time.111
Occurrence of migraine has been studied in patients with narcolepsy.112 A case-control
study in Germany found no increase in migraine in narcolepsy (n=96) patients compared to
controls. However, unspecified headache was increased (p<0.006).112 Another study in children
with headaches found an increased prevalence of narcolepsy, yet no association of narcolepsy with
migraine specifically.113 A Japanese study found an increase for migraine (p<0.0001), but not
headache, for narcolepsy patients compared to healthy controls.114
In a French case-control study performed by Barateau and colleagues, smoking and alcohol
use was increased in patients with narcolepsy and cataplexy (type 1) (n=243) compared to controls
for a 12-month period.115 However, heavy alcohol use was decreased and illicit drug use was low.
Blackwell et al, conducted a systematic review of published research related to cognitive
function and psychosocial well-being among pediatric narcolepsy patients.116 Eight studies
between 2005 and 2015 were available.117-124 Even though these studies were mainly of small
sample size and limited analyses, overall they suggested an increase in depression, anxiety, and
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low self-esteem among narcoleptic children. Additionally, these children were at risk of cognitive
impairment.
In summary, it appears that narcolepsy is associated with various comorbid conditions.
Additionally, these comorbidities span various body systems. Unfortunately, the incidence and
prevalence of narcolepsy makes thorough study of many of these comorbidities difficult. It cannot
be stressed enough the need for large population and health care claims studies to assess these
issues.
Pharmaceutical Treatment of Narcolepsy
When treatment of narcolepsy is necessary, the main focus of treatment is symptom
control.24 The typical approach is to treat narcolepsy associated excessive daytime sleepiness
(EDS) with stimulants.25;26 When patients present with co-occurring cataplexy and parasomnias
(e.g. hypnagogic hallucinations and sleep paralysis), the general approach is to treat with
antidepressants.25-27 This review will discuss the safety, effectiveness, and available general usage
information regarding pharmaceutical treatments for these narcolepsy associated symptoms. The
first section will be focused on EDS, since this condition is an essential and usually the most
obvious symptom to manifest in patients with narcolepsy.27;125;126 The subsequent section will
concentrate on pharmaceutical treatments for cataplexy, hypnagogic hallucinations, and sleep
paralysis symptom. This review will focus on treatments available in the United States. Because
few pharmaceutical treatments are available127 and publication of clinical studies regarding
treatment of patients with narcolepsy is limited, an attempt was made to retrieve and review all
relevant information.
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Excessive Daytime Sleepiness
The following drugs are used in the treatment of excessive daytime sleepiness (EDS)
associated with narcolepsy in the United States:24;26;27;125;127-131
•

Modafinil

•

Armodafinil

•

Sodium oxybate

•

CNS stimulants
o Methylphenidate
o Dextroamphetamine
o Amphetamine

All the medications listed above, modafinil, armodafinil, and sodium oxybate and the CNS
stimulants, methylphenidate, dextroamphetamine, amphetamine are currently FDA-approved for
the indication of narcolepsy-related EDS or general narcolepsy.126;128;129;131 This review will
discuss both limited interventional and observational study information available, treatment
suggestions, and associated adverse events.
Effectiveness and Use
Modafinil
Clinical trials have shown that pharmacological treatment of narcolepsy-related EDS may
be highly effective.128;132-136 Clinical trials of modafinil showed patient and physician assessed
reduction in daytime sleepiness, compared to placebo, while not affecting nighttime sleep.132;133
Additionally, statistically significant improvements in daytime sleepiness were observed in
narcoleptic patients treated with low and high dose modafinil, compared to placebo.133 Reduction
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in EDS was not dose dependent. The US Modafinil in Narcolepsy Multicenter Study Group
performed two placebo-controlled randomized double-blind studies.134;135 Both studies showed
statistically significant improvements in the Multiple Sleep Latency Test (MSLT), the
Maintenance of Wakefulness Test (MWT), and the Epworth Sleepiness Scale (ESS) for modafinil
compared to placebo. Low and high doses showed efficacy for 9 weeks, compared to placebo, and
continued to reveal clinical benefit during the 40-week open-label period. Study of modafinil as
single or combination agent for EDS has been shown effective and will be describe in the sodium
oxybate section.136
Split-dosing of modafinil has shown to be effective in treating sleepiness in narcolepsy
patients in a clinical trial.137 A randomized, placebo-control trial comparing dosing regimens in
55 adult patients showed that ESS and MWT measurements, compared to baseline, were improved
for low-dose (ESS-p<0.05; MWT-p<0.01), high-dose (ESS-p<0.0001; MWT-p<0.01) and splitregimen (ESS-p<0.05; MWT-p<0.01) groups after 3 weeks of treatment.
A longer-term study, 6-week crossover followed by 16-week open-label, was conducted to
assess modafinil efficacy using MWT and ESS in 69 patients with narcolepsy.138 Significant
decreases in EDS were observed for both measurements compared to baseline. Patient diaries also
reflect benefit of modafinil.
A systematic review of published modafinil trials was conducted by Golicki and
colleagues.139 Nine studies were included. Information from 4 studies showed a reduction in daily
somnolence, sleep attacks, and naps with modafinil compared to placebo. Three studies provided
MSLT data and revealed a statistically significantly (p<0.05) longer sleep latency for modafinil
compared to placebo.

Six studies provided information revealing greater maintenance of

31

wakefulness for modafinil compared to placebo, via MWT. ESS assessments also favored
modafinil.
To evaluate long-term treatment of pediatric patients with modafinil for EDS in narcolepsy,
chart reviews of 13 patients were conducted.140 Favorable results were reported by 90% of parents.
Among the 7 patients who underwent repeat MSLT, sleep latency significantly (p=0.02) improved
compared to baseline.
Armodafinil
Treatment of narcolepsy-related EDS with armodafinil has been investigated in clinical
studies.141;142 Low and high dose armodafinil for treatment of EDS was investigated in a doubleblind placebo-controlled trial of 196 patients.142 Significant increases in MWT were observed for
both armodafinil treatment groups. Additionally, ESS, Clinical Global Impression of Change, and
evaluations of patient diaries, fatigue, and cognitive performance all revealed improvement with
treatment with armodafinil.

An open-label, multi-national, extension study involving 156

narcolepsy patients assessed armodafinil effectiveness in treating EDS.141 Armodafinil improved
daytime wakefulness as measured by ESS (no tests of significance provided) after 1-year of
treatment.
Sodium oxybate
Clinical studies have shown that sodium oxybate is effective in reducing EDS in narcolepsy
patients.136 A multicenter, international, double-blind, placebo-controlled, 4-arm clinical trial was
conducted to assess sodium oxybate and modafinil, both singularly and in combination, for
reduction of EDS in patients with narcolepsy.136 After a 2-week modafinil treated baseline run-in
phase, patients were randomly assigned and treated during an 8-week period. Patients treated with
placebo showed a significant (p<0.001) reduction in sleep latency measured by MWT. However,
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sodium oxybate was equally as effective as modafinil for treatment of EDS. The combination of
modafinil and sodium oxybate statistically (p<0.001) increased sleep latency. ESS scores were
also improved with sodium oxybate and the modafinil/sodium oxybate combination.
A 42-center, international, double-blind, placebo-controlled trial of 228 adult patients
with narcolepsy and cataplexy assessed the effect of sodium oxybate on reduction of EDS over an
8-week period.143 EDS was effectively reduced with sodium oxybate treatment when evaluated
by ESS, with 6 and 9-gram doses being statistically significant (p<0.001). MWT revealed
significant (p<0.001) improvement for the 9-gram dose (>10-minute increase). Analyses of patient
data from this study cohort also revealed that sodium oxybate significantly increased stage 3 and
4 length of sleep in patients receiving 9 grams, while 6 and 9-gram doses reduced nighttime
awakenings and Stage 1 sleep.144 Delta power increased for all dosage groups.
A review of two European pediatric populations treated with sodium oxybate for
narcolepsy was conducted.145 Of the 27 patients, 85.2% were determined to have a positive impact
on EDS.
A meta-analysis, including 9 clinical trials of sodium oxybate for treatment of narcolepsy,
assessed EDS and sleep attack symptoms.146 Five studies allowing for analysis of EDS showed
significant reduction of sleepiness with administration of sodium oxybate, as measured by ESS.
Occurrence of sleep attacks assessment was attempted. Available data from 5 studies showed that
sodium oxybate was associated with a weekly reduction in daytime sleep attacks. However, when
data was analyzed by daily parameters, differences were not significant.
Dextroamphetamine and Amphetamines
Amphetamines have been researched for treatment of narcolepsy-related EDS. The few
available trials show that dextroamphetamine may be beneficial in treating daytime
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somnolence.147-149 Shindler and colleagues conducted a double blind, placebo-controlled, threeway crossover study of three sequential low and high dose drug formulations, including
dextroamphetamine, for 4 weeks periods in 20 patients diagnosed with narcolepsy.147
Dextroamphetamine was effective in reducing daytime sleepiness using both low and high doses.
High dose was slightly more effective than low dose and statistically significantly better than
placebo. The trial did not display any differences among the 3 active treatment groups. Even
though the study was small (n=20) with a wide age range (28-65 years of age), significant changes
in narcolepsy symptoms was observed.
Two other small studies, conducted by Mitler and colleagues, assessed the effects of
dextroamphetamine on EDS in narcolepsy.148;149 A small study of various drugs assessed the
effects of dextroamphetamine (n=5), compared to placebo, on EDS in narcolepsy.148 A significant
(p<0.05) reduction in daytime sleepiness, compared to baseline, was observed for patients treated
with both low and high dose dextroamphetamine over a 7-day period. This same study center
evaluated 8 subject pairs in a 4-week double-blind, placebo-controlled trial of dextroamphetamine
for EDS.149 MSLT assessment revealed that dextroamphetamine increased sleep latency in both
active and placebo treated patients. Additionally, narcolepsy patients treated with higher dose
dextroamphetamine were able to function similar to untreated healthy subjects while performing
daytime activities.
Methylphenidate
Limited clinical study evidence is available for the efficacious use of methylphenidate for
the treatment of narcolepsy associated EDS. A small trial, including patients treated with
methylphenidate (n=6), was conducted in narcolepsy patients and healthy individuals.150 Low,
medium, and high doses of methylphenidate were associated with a statistically significant
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reduction in daytime somnolence compared to placebo treated individuals. The study size and
unique comparison group (placebo treated healthy individuals) limit the generalizability to
narcoleptic patients. However, all three dosage groups observed significant improvement in their
EDS.
Suggested Therapy
Sodium oxybate, modafinil, and armodafinil are widely considered first-line therapies for
EDS associated with narcolepsy.27;126;128;151 Second-line therapies include higher dose modafinil
and methylphenidate.27;126;128;151 Amphetamines have been considered third-line therapy, mainly
due to potential abuse and risk-benefit profiles.126;128;151
Drug-resistant EDS may be treated on a case-by-case basis with a combination of
treatments.126
Most treatments are aimed at young and older adults. Studies and guidelines for treatment
of pediatric narcolepsy-related EDS are rare and evidence-based guidelines have not been
published based on pediatric studies. Any pediatric treatment recommendations have been derived
from adult treatment approaches.152 Only methylphenidate, dextroamphetamine, and sodium
oxybate (October 2018) have FDA-approved indications in children.152
Tolerability and Safety
Modafinil/Armodafinil
Modafinil and Armodafinil have been associated with headache, nausea, nervousness,
anxiety,

insomnia,

nasopharyngitis,

upper

respiratory

tract

infection,

and

rhinitis.26;126;128;134;139;141;153 Serious hypertension has been rarely noted.141 Severe skin rashes
such as Stevens-Johnson syndrome have less frequently been observed.125;128;153
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Sodium Oxybate
Sodium oxybate is generally well tolerated. However, adverse events experienced include
dizziness, headache, nausea, weight loss, restless leg syndrome, parasomnias, confusion, anxiety,
and depressive symptoms.126 Patients treated with sodium oxybate have experienced nausea,
sleep-walking, confusion upon waking, nocturia, dizziness, hypertension, and headaches. More
serious events, but less common, have been observed such as suicidal ideation, insomnia, tremor,
dissociative feelings, constipation, coma, seizures, bradycardia, and respiratory depression.26;125
Methylphenidate and Dextroamphetamine
The adverse event profiles for methylphenidate and dextroamphetamine are somewhat
similar.125 More frequent events experienced by patients include insomnia, anxiety, irritability,
weight loss, decreased appetite, stomach ache, dry mouth, tremor, tachycardia, palpitations,
hypertension, tics, and headache. Events observed less frequently are constipation, confusion,
muscle cramps, epistaxis, and hematuria.26;125;126;128;153 Dextroamphetamine overdose has been
associated with hallucinations, irritability, and aggressive behavior.125
Cataplexy, Hypnagogic Hallucinations, and Sleep Paralysis
The following drugs are used in the treatment of narcolepsy associated cataplexy,
hypnagogic hallucinations, and sleep paralysis in the United States: 24;26;27;125;127;130;130;131;151;154-162
•

Sodium oxybate (Xyrem)

•

Serotonin-noradrenaline reuptake inhibitors (SNRIs)
o Venlafaxine
o Duloxetine

•

Norepinephrine reuptake inhibitor (NRI)
o Atomoxetine
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•

Selective serotonin reuptake inhibitors (SSRIs)
o Fluoxetine
o Citalopram

•

Tricyclic antidepressants (TCAs)
o Clomipramine
o Imipramine
o Desipramine
o Protriptyline

•

MAO-inhibitor
o Selegiline

•

Amphetamines

•

Methylphenidate
Of all the medications listed above, only sodium oxybate (Xyrem Prescribing Information

2018 – Jazz Pharmaceuticals) is currently FDA-approved for the indication of cataplexy.26;129;162
No drugs have a specific FDA-approved indication for hypnagogic hallucinations or sleep
paralysis in the U.S.131;154;163 The following paragraphs will generally discuss the limited safety
and effectiveness information regarding treatment of cataplexy, hypnagogic hallucinations, and
sleep paralysis found in the medical literature based on clinical use. Most medications have not
been assessed via clinical trials for treatment of cataplexy.

155;156

The treatment of hypnagogic

hallucinations and sleep paralysis generally varies among patients and consistent/chronic
pharmacological treatment is generally not recommended. 126 A dearth of medical literature exists
regarding the treatment and tolerability using medications for hypnagogic hallucinations and sleep
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paralysis.156 However, any comments related to these conditions/symptoms will be provided if
available.
Effectiveness and Use
Sodium Oxybate
Clinical trials have shown that sodium oxybate is effective in reducing the median number
of cataplectic attacks, with dose-dependent efficacy (4.5g – 57%, 9g - 88%) when compared to
placebo.154;157 Another trial showed effectiveness only at the high dose.158 Twelve-month and 12week open-label studies have also shown clinical efficacy with 3-9 g doses.154;159;160 Interestingly,
a study examining changes in cataplexy showed that withdrawal of sodium oxybate therapy
following long-term (7-44 months) resulted in an increase (p<0.001) in cataplexy episodes over 2
weeks compared to continued treatment.164
These studies also investigated the efficacy of sodium oxybate for the treatment of
hypnagogic hallucinations and sleep paralysis. The open-labeled studies showed similar dosedependent reductions of both conditions with the highest dose, 9g, reducing occurrences by 76%90%. However, the controlled trials showed no differences between sodium oxybate and placebo
for hypnagogic hallucinations or sleep paralysis.161
A review of two European pediatric populations treated with sodium oxybate for
narcolepsy was conducted.145 Of the 27 patients, 81.5% were determined to have a positive impact
on cataplectic symptoms.
A meta-analysis (previously discussed), including 9 clinical trials of sodium oxybate for
treatment of narcolepsy, assessed cataplexy attacks.146 Of the few studies assessing cataplexy,
daily and weekly statistically significant reductions in cataplexy attacks were observed.
Hypnagogic hallucinations and sleep paralysis could not be analyzed.
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Antidepressants
Other than sodium oxybate, the main pharmacological strategy for treating cataplexy
involves the use of antidepressants.126;130;131;156;161 However, few studies have been conducted
focusing on the treatment of cataplexy with antidepressants and effectiveness has mainly been
demonstrated via clinical case reports and use of patient diaries.127;131;151;156 The most detailed
systematic review of studies on the use of antidepressants for narcolepsy was performed for a
Cochrane review.165 This review found few studies with efficacy evidence and suggested that
patients may be treated with antidepressants if they so choose.
Other Studies
A systematic review of published modafinil trials was conducted by Golicki and
colleagues.139 Of the 4 studies that provided data regarding cataplexy, none showed a significant
reduction in cataplexy with modafinil treatment.
Suggested Therapy
Sodium oxybate is widely considered first-line therapy for cataplexy.126;130;131;156;161
However, the SNRI venlafaxine and TCAs (clomipramine) have commonly been used to treat
cataplexy, with TCAs effecting the condition much faster than sodium oxybate.1;126;155
Venlafaxine has also been considered a first-line therapy, while clomipramine is considered
second-line therapy.1;126 Another SNRI, duloxetine, and NRIs such as atomoxetine have been
employed with some success and are considered second-line therapies.1;126 The SSRIs fluoxetine
and citalopram have been used by some clinicians, however these are generally considered second
or third line treatments.1

When cataplexy is intractable, combination therapies are often

required.126 The MAO-inhibitor selegiline has also been employed as a treatment for cataplexy
and may be considered as optional treatment.130;131;156;161
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As needed, stimulants such as amphetamines and methylphenidate have been used to treat
cataplexy. Little information is known of their efficacy.155
When treatment of hypnagogic hallucinations and sleep paralysis is required, sodium
oxybate and venlafaxine are the preferred front line therapies.126;156;161 Other antidepressants may
be considered as needed.130;161
Tolerability and Safety
Sodium oxybate is generally well tolerated and is considered first-line therapy,1;126;154;160;161
however serious adverse events have been reported and careful titration is required.1 Adverse
events reported from trials in adults were usually mild (e.g. nausea, enuresis, vomiting, dizziness,
and headaches). Withdrawal from the studies did occur due to serious adverse events. These
included (acute confusional state, agitation, and elevated liver enzymes.154;157;158
retrospective study reviewed adverse outcomes in 8 pediatric patients.166

One

Two patients

discontinued treatment due to suicidal ideation, nightmares, and dissociated feelings. In the 12week open-label study, 9 of 202 (4.5%) discontinued due to adverse events.160 These events
included psychosis, migraine, dizziness, nausea, anxiety, fatigue, insomnia, abdominal pain,
shortness of breath, and depression.
The 2018 Xyrem professional package insert notes Warnings and Precautions for central
nervous system depression, abuse/misuse, respiratory depression, sleep disordered breathing,
depression, suicidality, parasomnias, psychiatric events, and others. Additionally, care must be
taken not to prescribe this medication to patients with concurrent depression or untreated sleep
apnea, as these conditions may be exacerbated.1
The antidepressants appear to be well tolerated. However, adverse events have been
reported and severe rebound cataplexy is a concern with abrupt withdrawal of all anti-
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depressants.1;126;131;151 Venlafaxine appears to be the most tolerated antidepressant with side
effects mainly consisting of headache, dry mouth, hyperhidrosis, constipation, nausea, and
dizziness.1;126

Also reported have been exacerbation of depression, neuroleptic-malignant

syndrome, and rare cases of serotonin syndrome.153 Atomoxetine main adverse events include dry
mouth, cough, decreased appetite, constipation, nausea, and dizziness.1 Clomipramine has been
reported to exhibit more severe dry mouth, hyperhidrosis, constipation, prolongation of QT
interval, tremor, weight gain, vomiting, syncope, tachycardia, and impotence.1;153 Additionally,
TCAs have been associated with increased sedation, orthostatic hypotension, and cardiac
arrhythmias in older patients.151 The SSRIs have been well tolerated and associated mainly with
insomnia, mental stimulation, and reduced sexual function.1;126 Selegiline should be used with
caution because of its association with severe drug and food interactions.156 It is also important to
note that serious comorbidities may be exacerbated with all cataplexy treatments and clinicians
should make note of any changes in patient symptoms.131
The less often used stimulants, such as amphetamines, and methylphenidate have been
associated with cardiac events and require close follow-up.155
Review of the effectiveness and tolerability/safety reveals that the majority of treatment
practice guidance and regimens are based on clinical experience and expert opinions. Of all the
pharmacological treatment options, sodium oxybate has been investigated the most in clinical
studies and appears to have the best safety profile.

However, cataplexy, hypnagogic

hallucinations, and sleep paralysis are most likely best treated on a case-by-case basis taking into
account the patient’s complete medical profile and preferences for treatment.
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Truven MarketScan Database
Validation of Single Claims and Appropriateness for Conducting these Studies
The Truven MarketScan Database is an appropriate source of data for conducting the
studies described in this dissertation. A validation of single claim narcolepsy patients was
performed in the Truven MarketScan database to confirm that these patients are similar to patients
with multiple narcolepsy claims and confirmatory diagnostic procedures.11 Patients with single
claims for narcolepsy were compared to controls and narcolepsy patients with multiple diagnoses
and confirmatory PSGs and MSLTs, with respect to service utilization and healthcare costs. These
comparisons confirmed that single claim narcolepsy patients were very similar to multiple claim
narcolepsy patients and should be included in narcolepsy studies using the Truven MarketScan
database. This information is relevant for the study assessing prevalence and incidence of
narcolepsy.
Investigations into the influences of H1N1 vaccination and infections on the immune
system and subsequent development of narcolepsy have shown an increase in narcolepsy within
months of exposure, with some patients diagnosed within weeks.69;71;75-77;95;97 These studies
support the use of the Truven MarketScan database for a case-control study of the potential
increase in respiratory infection diagnoses during the 18 months prior to the diagnoses of incident
narcolepsy, compared to controls without history of narcolepsy.
Obtaining Data and General Construction of the Dissertation Database
The 2008-2010 MarketScan Research Database provided by Truven Health Analytics
captures person-specific information related to various inpatient, outpatient, and prescription drug
claims from a selection of large employers, health plans, and government and public organizations
(Truven Health MarketScan Research Database Dissertation Support Users Guide). The database
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for 2008-2010 contains approximately 18 million lives and more than a billion
observations/records. Because of the size of the database, Truven was required to deliver the
dissertation data on multiple DVDs. Therefore, the database was divided into various subsets of
data. These overall subset categories were:
•

A – Annual Enrollment Summary

•

D – Outpatient Pharmaceutical Claims

•

F – Facility Header

•

I – Inpatient Admissions

•

O – Outpatient Services

•

P – Aggregated Populations

•

S – Inpatient Services

•

T – Enrollment Detail
Utilizing SAS macros, data sets were combined into yearly files and categories, and

relevant variables were maintained. As data sets were combined, the number of observations was
then checked against the number of observations noted in the corresponding Data Quality Reports.
Once the overall dataset was constructed, all enrollees without continuous enrollment from 2008
through 2010 were removed. Datasets were created separately for the two manuscripts. Final
analysis datasets included key variables for prevalent narcolepsy, incident narcolepsy, cataplexy
status, narcolepsy diagnosis date, index date, infection groupings, infection diagnosis date, case or
control status, age, geographical region, and gender.
Appendix A represents the general flow of steps/activities that occurred in order to create
the two final databases utilized in this dissertation.
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CHAPTER TWO
MANUSCRIPT 1: PREVALENCE AND INCIDENCE OF NARCOLEPSY IN A U.S.
HEALTH CARE CLAIMS DATABASE, 2008-2010
Introduction
Narcolepsy is a chronic neurological disorder characterized primarily by excessive daytime
sleepiness (EDS) and, in many cases, cataplexy.1;2;4;167 Cataplexy is characterized by one or more
sudden short term (<2 minutes) losses of muscle tone (often due to an emotional trigger), yet
consciousness is retained.167 Patients with narcolepsy may experience various psychiatric and
physical comorbid diseases and mortality at an increased rate compared to the general population.510

Additionally, patients with narcolepsy experience approximately a doubling of various annual

healthcare related facility visits, transactions, and costs comparatively.11
Narcolepsy, with and without cataplexy, appears to be a rare sleep disorder with wide and
varying incidence and prevalence estimates.1;1;12-16;21;43 It has been noted that incidence and
prevalence for narcolepsy may be difficult to obtain, with few large epidemiological studies
available.12-20 Limited studies have been conducted in the U.S. and none were found assessing
incidence and prevalence, including stratification by cataplexy status, in both children and adults
based on a large health care claims database.18-20
Possibly the earliest large-scale, population-based, study of both the incidence and
prevalence of narcolepsy was conducted in Olmsted County, MN.18 For the period 1960 to 1989,
the mean annual incidence of narcolepsy was 1.37/100,000 persons per year (with cataplexy:
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0.74/100,000 persons per year). Prevalence in 1985 was 56.3/100,000 persons (with cataplexy:
35.8/100,000).

Few other U.S. based studies investigated the prevalence and incidence of

narcolepsy. In adults, the prevalence of overall narcolepsy in King County, Washington was
30.6/100,000 persons (with cataplexy: 21.8/100,000 persons).19 Incidence was estimated to be
0.39 to 0.62/100,000 person-years. In U.S. military personnel, the incidence of narcolepsy ranged
from 14.6/100,000 person-years to 27.3/100,000 person-years.20 Incidence rates were 50 to 100%
greater in women, compared to men, for most years. Interestingly, research from the Wisconsin
Sleep Cohort revealed that the prevalence of narcolepsy without cataplexy may actually be up to
3 times greater than that for narcolepsy with cataplexy, an unexpected result.21;43
A few non-U.S. based studies of prevalence and incidence of narcolepsy have been
conducted. Using the Ullanlinna Narcolepsy Scale (UNS), a random survey of Norwegian citizens
20 to 60 years of age revealed the prevalence of narcolepsy with cataplexy to be approximately
22/100,000 persons.53 This proportion was similar to that obtained in the Finnish Twin Cohort
study (26/100,000 persons).62 The prevalence of narcolepsy with cataplexy among Korean
adolescents was estimated to be 15/100,000 persons, while narcolepsy without cataplexy was
34/100,000.54 One European five-country random sample interview study found narcolepsy
prevalence to be 47/100,000 persons52, while another multi-national European linked healthcare
database study found the overall incidence of narcolepsy to be 0.93/100,000 person-years.55
Previous U.S.-based studies have been somewhat limited due to regionally restricted
populations, smaller age distributions, or size of the populations studied. Because of these
limitations, their possible influence on the prevalence and incidence estimates of a rare condition,
and the various health concerns related to narcolepsy, we conducted this study of the prevalence
and incidence of narcolepsy, with and without cataplexy, using a large U.S. health care claims
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database. Using a claims database with sufficient population size, wide age distributions, and
expanded U.S. regional coverage allows for more precise estimates of the prevalence and incidence
of a disease such as narcolepsy.
Methods
Study Design
We conducted a cross-sectional study to estimate the prevalence and incidence of
narcolepsy using the Truven Health MarketScan Commercial Dissertation Database (THMCDD)
for the period January 1, 2008 to December 31, 2010. The THMCDD encompasses approximately
100 private-sector health insurers, covering over 18 million people under the age of 66, and more
than a billion observations/records in the U.S.

The THMCDD captures person-specific

information related to various inpatient, outpatient, and prescription drug claims. This includes
both diagnoses and procedure claims. A unique enrollee identification number is assigned to each
individual. These enrollees are “de-identified” as the database did not contain personal identifying
information. This is in compliance with the Health Insurance Portability and Accountability Act.
This study was reviewed by the University of South Florida Institutional Review Board (IRB) who
determined it exempt from further review.
Study Population
The eligible study population was all enrollees in the THMCDD, 65 years of age and
younger, continuously enrolled for years 2008 to 2010. Continuously enrolled individuals were
required to have enrollment during each month for the entire 36 month period.
Measures
Narcolepsy, with and without cataplexy, was identified using the International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM = 347.0, 347.00,

46

347.01, 347.1, 347.10, or 347.11). Narcolepsy without cataplexy was defined as any enrollee who
had claims only for ICD-9-CM 347.00 or 347.10. Narcolepsy with cataplexy was defined as any
enrollee who had at least one claim for ICD-9-CM 347.01 or 347.11. The shortened codes ICD9-CM 347.0 and 347.1 were included in case claims were made in which the cataplexy status
(defined by the fifth digit of the code: 0=without cataplexy, 1=with cataplexy) was not identified
for any reason. Both primary (ICD-9-CM 347.00 and 347.01; identified by the fourth digit “0”)
and secondary (ICD-9-CM 347.10 and 347.11; identified by the fourth digit “1”) were included in
the analyses.
A prevalent case was defined as any enrollee with a claim for narcolepsy during the study
period.

To be included as an incident case, first, enrollees had to have a claim for a

polysomnography (PSG) (CPT 95808, 95810, 95811, or ICD-9-CM 89.17) within 2 days of a
multiple sleep latency test (MSLT) (CPT 95805 or ICD-9-CM 89.18). After obtaining the
enrollees that met the PSG and MSLT criteria, incidence was calculated using three definitions:
1.) MSLT claim within 180 days, before or after, of the first narcolepsy claim; a follow-up
diagnosis for narcolepsy must be observed for cases in which the multiple sleep latency test is
recorded after the first narcolepsy diagnosis, 2.) MSLT claim within 180 days before, or 30 days
after, the first narcolepsy claim; a follow-up diagnosis for narcolepsy must be observed for cases
in which the multiple sleep latency test is recorded after the first narcolepsy diagnosis, and 3.)
MSLT claim within 180 days before the first narcolepsy claim. Three incidence criteria were
employed to account for possible differences in temporality or delays in reporting procedures,
diagnosis claims, or follow-up visits. The age of an enrollee was considered the age at which the
enrollee met the criteria for narcolepsy. Otherwise, the age was defined as the age at the mid-year
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of the enrollment period, 2009. Additionally, gender (male or female) and U.S. region (northeast,
north central, south, west, and unknown) was noted for each enrollee.
Statistical Analysis
Prevalence was calculated by dividing the number of narcolepsy patients during the period
(2008 to 2010) by the total number of continuous period enrollees. This was expressed as the
number of cases/100,000 persons. Incidence was calculated by dividing the number of incident
cases by 3 (the number of years in the study period), then dividing by the number of continuous
period enrollees. This average annual incidence was expressed as new cases/100,000 persons per
year.
Prevalence and incidence were calculated for the overall population, by gender, by age
groups in years (0-10, 11-20, 21-30, 31-40, 41-50, and 51-65) and by U.S. region. Incidence was
further calculated by stratifying the 11 to 40 year old population by 3 year groupings (11-13, 1416, 17-19, 20-22, 23-25, 26-28, 29-31, 32-34, 35-37, and 38-40). For all prevalence and incidence
evaluations, calculations were performed separately for all narcolepsy, narcolepsy without
cataplexy, and narcolepsy with cataplexy. Additionally, Clopper-Pearson exact 95% Confidence
Intervals (CI) were calculated for all prevalence and incidence estimates.
Our intention was to assess the prevalence and incidence of narcolepsy. Populations were
not compared based on formal statistical tests.168;169 However, descriptive statistics are presented
with 95% confidence intervals, allowing for general comparisons and comments regarding
potential prevalence and incidence differences between/among age groups, genders, and
geographical regions.
All analyses were performed using SAS software version 9.4 (SAS Institute, Inc.).
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Results
In the THMCDD, there were 8,444,517 continuous enrollees for the period 2008-2010.
Overall, age and gender specific prevalence proportions are provided in Table 2.1. Overall
prevalence of narcolepsy was 79.4/100,000 persons, with females (91.8/100,000 persons) having
a greater prevalence than males (65.8/100,000 persons). The highest prevalence occurred among
those 21 to 30 years of age (overall: 128.5/100,000 persons; females: 154.9/100,000 persons;
males: 97.7/100,000 persons). Prevalence proportions were greater among females compared to
males for all age groupings, except for those 0-10 years of age.
Prevalence by cataplexy status revealed generally similar patterns compared with the
overall prevalence data. Prevalence of narcolepsy without cataplexy was 65.4/100,000 persons,
with females (75.0/100,000 persons) having a greater prevalence than males (54.8/100,000
persons). The highest prevalence occurred among those 21 to 30 years of age for females and
males combined (102.5/100,000 persons) and females alone (124.2/100,000 persons). However,
in males, prevalence was slightly greater among those 31 to 40 years of age (79.2/100,000 persons)
compared to 21 to 30-year olds (77.2/100,000 persons). Similar to overall prevalence, proportions
were greater among females compared to males for all age groupings, except for those 0-10 years
of age.
Prevalence of narcolepsy with cataplexy was 14.0/100,000 persons, with females
(16.8/100,000 persons) having a greater prevalence than males (10.9/100,000 persons). The
highest prevalence occurred among those 21 to 30 years of age (overall: 26.0/100,000 persons;
females: 30.7/100,000 persons; males: 20.5/100,000 persons).

Prevalence proportions were

greater among females compared to males for all age groupings, except for those 0-10 years of age
where prevalence was 0.9/100,000 persons for each.
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Age and gender specific incidence proportions using all three years of data are provided
in Table 2.2. For the first incidence criteria, an MSLT claim within 180 days before or after the
first narcolepsy claim, overall average annual incidence was 7.67/100,000 persons per year.
Females were associated with greater average annual incidence compared to males (9.36 vs.
5.82/100,000 persons per year). The greatest incidence occurred among enrollees 21 to 30 years
of age (overall: 13.97/100,000 persons per year; females: 17.41/100,000 persons per year; males:
9.97/100,000 persons per year). Incidence proportions were greater among females compared to
males for all age groupings, except for those 0-10 years of age. Incidence was higher for
narcolepsy without cataplexy compared to narcolepsy with cataplexy (6.02 vs. 1.65/100,000
persons per year). Age and gender trends for incidence, considering cataplexy status, were similar
to the overall incidence proportions. Females were associated with greater average annual
incidence compared to males for narcolepsy without cataplexy (females: 7.36/100,000 persons per
year; males: 4.57/100,000 persons per year) and with cataplexy (females: 2.0/100,000 persons per
year; males: 1.26/100,000 persons per year). The greatest incidence occurred among enrollees 21
to 30 years of age without cataplexy (overall: 9.96/100,000 persons per year; females:
12.64/100,000 persons per year; males: 6.84/100,000 persons per year) and with cataplexy
(overall: 4.02/100,000 persons per year; females: 4.78/100,000 persons per year; males:
3.13/100,000 persons per year). Incidence proportions were greater among females compared to
males for all age groupings, except for those 0-10 years of age.
For the second incidence criteria, an MSLT claim within 180 days before, or 30 days
after, the first narcolepsy claim, overall average annual incidence was 7.13/100,000 persons per
year. Females were associated with greater average annual incidence compared to males (8.68 vs.
5.43/100,000 persons per year). The greatest incidence occurred among enrollees 21 to 30 years
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of age (overall: 12.42/100,000 persons per year; females: 15.42/100,000 persons per year; males:
8.92/100,000 persons per year). Incidence proportions were greater among females compared to
males for all age groupings, except for those 0-10 years of age. Incidence was higher for
narcolepsy without cataplexy compared to narcolepsy with cataplexy (5.65 vs. 1.48/100,000
persons per year). Age and gender trends for incidence, considering cataplexy status, were similar
to the overall incidence. Females were associated with greater average annual incidence compared
to males for narcolepsy without cataplexy (females: 6.90/100,000 persons per year; males:
4.29/100,000 persons per year) and with cataplexy (females: 1.78/100,000 persons per year; males:
1.15/100,000 persons per year). The greatest incidence occurred among enrollees 21 to 30 years
of age without cataplexy (overall: 8.89/100,000 persons per year; females: 11.24/100,000 persons
per year; males: 6.14/100,000 persons per year) and with cataplexy (overall: 3.53/100,000 persons
per year; females: 4.18/100,000 persons per year; males: 2.78/100,000 persons per year).
Incidence proportions were greater among females compared to males for all age groupings, except
for those 0-10 years of age.
For the third incidence criteria, an MSLT claim within 180 days before the first narcolepsy
claim, overall average annual incidence was 4.87/100,000 persons per year. Females had a greater
average annual incidence compared with males (5.85 vs. 3.80/100,000 persons per year). The
greatest incidence occurred among enrollees 21 to 30 years of age (overall: 7.76/100,000 persons
per year; females: 9.35/100,000 persons per year; males: 5.91/100,000 persons per year).
Incidence proportions were greater among females compared to males for all age groupings.
Incidence was higher for narcolepsy without cataplexy compared to narcolepsy with cataplexy
(4.01 vs. 0.86/100,000 persons per year). Age and gender trends for incidence, considering
cataplexy status, were similar to the overall incidence. Females were associated with greater
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average annual incidence compared to males for narcolepsy without cataplexy (females:
4.83/100,000 persons per year; males: 3.10/100,000 persons per year) and with cataplexy (females:
1.01/100,000 persons per year; males: 0.69/100,000 persons per year). The greatest incidence
occurred among enrollees 21 to 30 years of age without cataplexy (overall: 5.94/100,000 persons
per year; females: 7.16/100,000 persons per year; males: 4.52/100,000 persons per year) and with
cataplexy (overall: 1.82/100,000 persons per year; females: 2.19/100,000 persons per year; males:
1.39/100,000 persons per year). Incidence proportions were greater among females compared to
males for all ages in those without cataplexy. Among patients with cataplexy, female incidence
proportions were higher in the age groups 21 years and older. The two younger age groups were
associated with higher incidence in males.
The average annual incidence proportions for 3-year groupings among enrollees 11 to 40
years of age is provided in Table 2.3. For all three incidence criteria by timing of MSLT, the 20
to 22 year old enrollees had the highest average annual incidence of all narcolepsy among all age
groups (16.52, 15.99, and 10.37/100,000 persons per year). This age group was also associated
with the highest incidence proportions in patients with cataplexy (5.10, 4.75, and 2.64/100,000
persons per year). The only group that did not observe this trend was those without cataplexy and
an MSLT claim within 180 days before or after the first narcolepsy claim. For this criteria, patients
17 to 19 years of age had the highest incidence, 11.63/100,000 persons per year. In patients
without cataplexy, the other two MSLT-based criteria revealed incidence proportions among 20 to
22 year olds of 11.25 and 7.73/100,000 persons per year.
Prevalence and incidence estimates by U.S. region are provided in Tables 2.4 and 2.5,
respectively. Overall prevalence of narcolepsy, without cataplexy, and with cataplexy were all
greatest in the North Central region (113.03, 95.56, and 17.47/100,000 persons, respectively).
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These were much higher than those observed in the West region (all narcolepsy: 45.13/100,000
persons, without cataplexy: 36.25/100,000 persons, with cataplexy: 8.87/100,000 persons). The
North Central region was also associated with the highest average annual incidence of all
narcolepsy for all three incidence criteria (12.70, 11.84, and 7.98/100,000 persons per year). The
incidence proportions in the North Central region were many times greater than those observed in
the West region, for all narcolepsy (2.78, 2.45, and 1.80/100,000 persons per year). This trend
was similar for those without cataplexy and with cataplexy.
Discussion
In this cross-sectional study, we found both the prevalence and incidence of narcolepsy,
with and without cataplexy, to be somewhat higher than most estimates found in the few previously
conducted studies, and similar to two other U.S.-based studies.20;21 Interestingly, we also found
consistent patterns regarding age of occurrence, gender and U.S. regional differences. These
differences held whether liberal, moderate, or more conservative definitions of incidence were
applied.
Generally, across the prevalence and incidence categories and age groups, we found that
females were approximately 50% more likely to have narcolepsy. This is both in contradiction
and agreement with previous estimates. Using a records-linked system and medical records for
patients diagnosed from 1960 to 1989 in Olmsted County, MN, the mean annual overall incidence
of narcolepsy was 1.37/100,000 persons per year (with cataplexy: 0.74/100,000 persons per
year).18 The overall proportion for men was higher than that for women (1.72 vs. 1.05/100,000
persons per year). Prevalence in 1985 was calculated as 56.3/100,000 persons (with cataplexy:
35.8/100,000). Overall prevalence in males was 72.5/100,000 persons, while the estimate in
females was 41.3/100,000 persons. Incidence was highest among 10 to 19 year olds (3.84/100,000
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per year). This group contributed to approximately half of all cases. The overall estimates were
lower than those we observed in the THMCDD, except for the prevalence found in males.
Few other U.S. based studies investigated the prevalence and incidence of narcolepsy. The
prevalence of narcolepsy with cataplexy and DQB1*0602 allele status in adults in King County,
Washington was estimated using a registry based on patient interviews and buccal swabs.19
Overall prevalence of narcolepsy was 30.6/100,000 persons (with cataplexy: 21.8/100,000
persons), with allele-positive patients associated with narcolepsy prevalence of 15.3/100,000
persons. Prevalence across most age groups was greater for women than men. Overall, these
estimates were lower than prevalence estimates we obtained. However, narcolepsy with cataplexy
prevalence among younger adults was similar to our study, while we found higher prevalence
among older adults. Another study assessed the incidence and prevalence of narcolepsy, regardless
of cataplexy status, in U.S. military personnel.20 Using the Defense Medical Surveillance System,
from 2004 through June 2013, annual incidence rates ranged from 14.6/100,000 person-years to
27.3/100,000 person-years for ages 18 years and above. Incidence rates were 50 to 100% greater
in women, compared to men, for most years. These findings were more in-line with those we
obtained. However, 25 to 30 year old military personnel experienced the greatest incidence of
narcolepsy. Whereas we found the greatest narcolepsy incidence in the THMCDD among those
20 to 22 years of age.
Our findings of higher prevalence and incidence of narcolepsy without cataplexy are
somewhat unexpected. These results may call into question the diagnostic accuracy of U.S.
healthcare providers and treaters. On the other hand, our observations from this large database
may be a real finding of increase in narcolepsy without cataplexy. It must also be considered that
providers in the U.S. may not have fully acknowledged and used the proper codes that differentiate
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narcolepsy with and without cataplexy when making insurance claims.11 Limitations from prior
smaller studies may not have allowed the detection of narcolepsy without cataplexy. Similar to
our findings, higher prevalence of narcolepsy without cataplexy compared to narcolepsy with
cataplexy was observed in the Wisconsin Sleep Cohort.21;43 Noting that there were limitations
within their cohort, these researchers estimated that prevalence of narcolepsy without cataplexy
was approximately 2 to 3 times greater than narcolepsy with cataplexy (0.13 to 0.20% vs. 0.07%).21
Our results, and those from the Wisconsin Sleep Cohort, are many times greater than those found
earlier for narcolepsy without cataplexy.
We found greater prevalence and incidence of narcolepsy than those observed in various
non-U.S. studies. Prevalence in these studies have generally approached 50/100,000 persons, with
incidence being much lower.52-55;62 However, one small study from Japan estimated narcolepsy
prevalence to be almost 600/100,000 persons.58
An increased risk for narcolepsy in various countries, during the time period of our study,
has been linked to adjuvanted influenza vaccines.55;65-78;170 However, these types of vaccinations
were generally not administered in the U.S.20;80 In a U.S.-based study, since signals for increased
risk of narcolepsy were not found in the FDA Vaccine Adverse Event Reporting System, the
Vaccine Safety Datalink database was assessed for records between 2006 and 2011.80 In over 1.5
million vaccinated, no cases of narcolepsy were recorded within 6 months of vaccination and only
2 cases occurred after the 2010 to 2011 period. Vaccination with the A(H1N1)pdm09 strain was
not associated with risk of narcolepsy. It has been suggested that the European AS03-adjuvanted
vaccine may have induced an immune response to brain hypocretin receptors, thus impacting the
regulation of sleep and narcolepsy.171;172

Since adjuvanted influenza vaccines were not

administered in the United states, and the A(H1N1)pdm09 strain was used both in Europe and the
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United States, this finding further helps to implicate the role of the AS03 adjuvant (e.g. used in the
Pandemrix vaccine) in the increase in narcolepsy found after vaccination. Of note, using the Kaiser
Permanente Northern California health plan data, 2 to 49 year old individuals vaccinated
(quadrivalent live-attenuated influenza) in 2013 to 2014 were compared to unvaccinated subjects
and were found to have similar incidence rates of narcolepsy.79 This live-attenuated vaccination
included A/H1N1. Even though this study period occurred a few years after the European
narcolepsy-associated adjuvant vaccine administration, it demonstrates the non-increase of risk
observed in this live-attenuated influenza vaccination, a different observation than that found with
previous adjuvanted influenza vaccines.
We found that the North Central U.S. region was associated with a strikingly greater
prevalence and incidence of narcolepsy than the other regions. Whereas the West had much lower
proportions. It cannot be completely ruled-out that these differences may be due to regional
diagnosis or recording practices. The THMCDD encompasses approximately 100 private-sector
health insurers. Differences in coverage of medications and formulary listings may influence
diagnoses so that particular patients receive certain medications that otherwise would not be
covered. Thus, artificially inflating the numbers of patients diagnosed with narcolepsy. Other
factors may contribute to the regional differences, such as diet, nutrient intake, or physical
exposures. For example, a European study found that vitamin D deficiency was associated with
narcolepsy with cataplexy.104 These researchers found an increased frequency of vitamin D
deficiency in these patients compared to controls (p<0.0238). Additionally, vitamin D deficiency
has been linked as a trigger for autoimmune disorders.173-176 Since a significant source of
circulating vitamin D has been shown to be related to sunlight exposure,177 the U.S. regional
difference in sunlight exposure may possibly be associated with the differences in narcolepsy rates
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and proportions. However, recently a larger case-control study of adult patients with narcolepsy
and cataplexy (n=174) and vitamin D levels did not find a difference between cases and controls,
after controlling for clinical and demographic variables.105
Another hypothesis that might be examined is that U.S. regional differences in infections
may contribute to the observed differences in narcolepsy prevalence and incidence. Few specific
infections have actually been investigated regarding the inducing of narcolepsy.90;91 Influenza
appears to be the most studied infection worldwide, with conflicting results regarding triggering
of narcolepsy.71;74;97-99 A case-control study found that Streptococcus pyogenes was associated
with development of narcolepsy within 3 years of infection.95 The relationship between infections,
including upper respiratory infections, and development of narcolepsy needs further investigation.
Differences in prevalence and incidence among U.S. regions may be due to varying
environmental toxins that have been theorized to be associated with increased risk for narcolepsy.63
A case-control study of DQB1*06:02 allele-positive adults to determine risks of exposures
occurring before 21 years of age found heavy metals (OR=4.7), high levels of woodwork
(OR=3.0), fertilizer (OR=3.1), and weed/bug killer (OR=4.5) to be associated with statistically
significant increases in risk. In the genetically susceptible population, environmental exposures
have been hypothesized to trigger narcolepsy development.64 Interestingly, a U.S. nationwide
study of human cadaver adipose samples has shown higher levels of environmental toxic exposures
in the North Central and South regions.178 These two regions were associated with the two highest
prevalence and incidence estimates in the THMCDD. However, this regional association must be
interpreted with caution since exposures may have occurred in a different region from where
narcolepsy was claimed. The regional differences observed require further investigation.
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Narcolepsy is a chronic neurological disorder characterized primarily by excessive daytime
sleepiness (EDS) and, in many cases, cataplexy.1;2;4;167 Narcolepsy patients experience various
psychiatric and physical comorbid diseases and mortality at an increased rate compared to the
general population.5-10 These findings of increased comorbid conditions and mortality may explain
some of the decrease in prevalence of narcolepsy found in our study in the older age groups.
Parkinson’s disease patients may exhibit excessive daytime sleepiness in 20 to 50% of cases and
may mask a true narcolepsy condition.179 Psychiatric conditions, such as major depressive
disorder, have been observed in patients with narcolepsy and other hypersomnias.9 The increased
daytime sleepiness observed in depression along with the observed increase in daytime sleep in
the older population and the interrelationships between age, depression, and sleepiness may
contribute to actual non-diagnosis of narcolepsy.180-182

Obstructive sleep apnea, causing

sometimes severe excessive daytime sleepiness and diagnosed in older adults, may contribute to
the underdiagnoses of narcolepsy. Sleep apnea, often coupled with obesity, has been found to be
a diagnosis given with high frequency before final diagnosis of narcolepsy has been made.183 Since
obesity has been associated with increase in narcolepsy diagnosis108, increases in weight, sleep
apnea, neurological disorders, various psychiatric conditions, and changes in age-related sleep
patterns184 may all contribute to the decrease in the prevalence observed in the older age groups.
Additionally, patients with narcolepsy experience approximately a doubling of various annual
healthcare related facility visits, transactions, and costs comparatively.11 For these reasons, further
assessments in large databases of the prevalence and incidence of narcolepsy, along with the
comorbid conditions, are beneficial in helping to determine disease patterns and the potential
impact on the public health and healthcare system.
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Studies performed in insurance claims databases present some limitations. Our study may
be subject to these typical issues.

For example, the THMCDD does not provide specific

demographics such as race, education, income, height, and weight. Therefore, we were not able
to stratify or assess changes in prevalence and incidence based on these variables. However, the
dataset did provide some important demographics such as gender and U.S. region. With the
substantial size of the THMCDD and the rarer occurrence of narcolepsy, this health claims
database, even with its inherent limitations, provides a very beneficial data source for these types
of assessments.
Our observations of much higher prevalence and incidence of narcolepsy among women
compared to men may possibly be due to the known gender differences in usage of the U.S.
healthcare system. A report by the Kaiser Family Foundation among adults 18 to 64 years of age,
found that women compared to men had higher proportions of routine clinician identification (81%
vs 68%), provider visits in the last two years (91% vs 78%), and a reported condition that required
continual monitoring (43% vs 30%).185

Our database of continuous enrollees contained

approximately 52% females and 48% males. Our observed higher proportion of narcolepsy claims
being in females may be due to women utilizing the healthcare system more than men and actually
attempting to have their narcolepsy diagnosed.

Thus, it is possible that our study has

underestimated the prevalence and incidence in men.

Therefore, we would have also

underestimated the overall prevalence and incidence of narcolepsy. However, the much greater
proportions in females, compared to males, that we have observed may actually be real.
Narcolepsy, with and without cataplexy is a serious condition. We believe it unlikely that the
greater reluctance of men to utilize their insurance coverage is enough to explain the large
differences observed.
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Another limitation of our study is the unavailability of medical records to validate the
narcolepsy diagnoses. Additionally, the number of claims for narcolepsy varied among the
enrollees and the possibility existed that some MSLT claims may have been recorded after the
diagnosis of narcolepsy was made. These issues could present a substantial problem to a smaller
study. To counter these issues, we assessed incidence using three definitions: liberal (MSLT claim
within 180 days, before or after, of the first narcolepsy claim; a follow-up narcolepsy claim was
also required after the MSLT), moderate (MSLT claim within 180 days before, or 30 days after,
the first narcolepsy claim; a follow-up narcolepsy claim was also required after the MSLT), and
conservative (MSLT claim within 180 days before the first narcolepsy claim). We also required
the MSLT to be coupled with a PSG, as has been previously suggested and practiced.35-37;39;40;42-46
Further, to determine if any delays in recording of service date substantially affected incidence
estimates, we reassessed the THMCDD to further restrict the requirement of PSG claim within 2
days of MSLT. Limiting the allowable service date of the PSG to within 1 day before the MSLT
changed the numbers of incident cases by less than 1%. Therefore the requirement of PSG within
2 days of MSLT was maintained.
In the current study, patients with a single claim represented 34.0% (n=2,276) of the overall
prevalent cases. The issue of variation in numbers of narcolepsy claims and whether enrollees
with single claims represented misdiagnosis or were inappropriate for inclusion has previously
been addressed in a validation study using the Truven Analytics MarketScan databases.7 The
validation study found that enrollees with single claims for narcolepsy were very similar to
enrollees defined by a stricter inclusion criteria.
Narcolepsy may take years to diagnose. Therefore, signs and symptoms of the conditions
would be missed using this type of study design and length. However, this is a study of narcolepsy
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diagnosis and claim. When the claim is made, the diagnosis won’t be “missed”. Thus, large
database designs are dependent on clinical recognition and official diagnosis of narcolepsy.
Regarding study length, we assessed claims from the beginning of 2008 through the end of 2010.
While the 3-year assessment most likely did not substantially impact prevalence (at least one
diagnosis of narcolepsy), the evaluation of incidence may have been affected. Follow-up of more
diagnoses would have been possible with a longer study period. Our three definitions of incidence
allowed for variations in reporting and all required narcolepsy diagnosis after PSG/MSLT.
However, there is still the possibility that some of our incident cases were actually not new cases,
due to a narcolepsy diagnosis before 2008 and the PSG/MSLT noted may have not been the first.
These situations would lead to a possible overestimation of the incidence.
In the present study, we included both primary and secondary narcolepsy. The designations
of primary and secondary are identified by the fourth digit of the ICD-9-CM code (“0” for primary
and “1” for secondary). There are multiple reasons for including both primary (often considered
idiopathic or due to autoimmune-related decrease in hypocretin) and secondary narcolepsy (caused
by an identified underlying condition, e.g. multiple sclerosis). Secondary narcolepsy is a much
rarer condition than primary narcolepsy. Differentiation of primary and secondary narcolepsy may
be difficult. In some cases, the development of narcolepsy may actually be due to another illness,
yet the etiology may not be identified. This would result in a diagnosis of primary narcolepsy.
Likewise, a diagnosis of secondary narcolepsy may be made when an underlying condition is
erroneously believed to cause the narcolepsy. Therefore inclusion of both primary and secondary
narcolepsies is prudent in a large epidemiological study of prevalence and incidence. However,
the results must be viewed with the consideration that the prevalence and incidence of primary
narcolepsy is most likely slightly lower than those obtained.
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Even though the THMCDD includes millions of enrollees with many observations, it only
contains information from private-sector health insurers. Medicare and Medicaid data are not
included. It has previously been observed that patients with narcolepsy suffer from comorbid
conditions at a higher rate than the general population.5-10 These conditions and more severe
medical situations often lead to reduction in employment, thus loss of income and reduction in
socioeconomic status.1;186-188 It is likely that a substantial number of patients with narcolepsy
might not have the opportunity to be included in this type of database due to loss of, or not ever
having, private insurance. Many patients may be required to transfer to Medicare or Medicaid in
the United States. Therefore, it is likely that our study may underestimate the prevalence and
incidence of narcolepsy with and without cataplexy. However, it is difficult to assess the true
impact due to changes of insurance coverage, both private and publicly funded, since other nonnarcolepsy conditions may suffer from the same migration of health coverage. Since Medicare is
mainly available to the older population, and our study included only patients 65 years of age and
younger, there was most likely little Medicare-related impacts on our assessed populations.
However, it must be considered that disabled patients under the age of 65 who receive Social
Security Disability Insurance (SSDI) would possibly have an impact on our study if sufficient
patients with narcolepsy become disabled or have infections that may have been included in our
study. More likely, the greater impact would have been from the potential Medicaid population.
These situations affect both the numerator and denominator for both prevalence and incidence
calculations. The preferred next steps for prevalence and incidence evaluation of narcolepsy with
and without cataplexy would be to conduct a similar study among Medicare and Medicaid patients.
An additional limitation of the study is the inclusion of only those patients with continuous
enrollment over the entire study period. This limits the study in that those populations who may
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typically enroll for only short periods of time are not represented in the final analysis dataset.
However, the requirement for continuous enrollment is essential for tracking of patients. This
helps to avoid over inclusion of subjects. Unfortunately, some true incident cases were most likely
not included. Thus, our study probably underestimated the incidence of narcolepsy.
In conclusion, we observed higher prevalence and incidence of narcolepsy compared to
most previous studies. Women were associated with approximately 50% increased proportions
compared to men. We also found that the greatest prevalence and incidence of narcolepsy occurred
in patients in their early 20s, and those residing in the North Central region of the U.S. Perhaps
most striking was the observation of much greater proportions of narcolepsy without cataplexy
compared to narcolepsy with cataplexy. Increased awareness and early identification among
healthcare providers for signs and symptoms of narcolepsy is critical in helping this population of
patients manage this burdensome condition.
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Table 2.1 – Prevalence of Narcolepsy, by Age Group and Gender, 2008-2010
Narcolepsy, Regardless of Cataplexy Diagnosis
Prevalent Cases
Population

Prevalence per 100,000 (95% CI)*

Age
0-10

F
28

M
36

Total
64

F
562,675

M
587,581

Total
1,150,256

11-20

411

344

755

664,926

681,609

1,346,535

21-30

519

281

800

334,993

287,654

622,647

31-40

880

551

1,431

666,818

579,759

1,246,577

41-50

1,033

618

1,651

921,652

805,774

1,727,426

51-65

1,177

825

2,002

1,256,406

1,094,670

2,351,076

Total

4,048

2,655

6,703

4,407,470

4,037,047

8,444,517

Narcolepsy, Without Cataplexy Diagnosis
Prevalent Cases

Population

F
23

M
31

Total
54

F
562,675

M
587,581

Total
1,150,256

11-20

311

266

577

664,926

681,609

1,346,535

21-30

416

222

638

334,993

287,654

622,647

31-40

710

459

1,169

666,818

579,759

1,246,577

41-50

856

532

1,388

921,652

805,774

1,727,426

51-65

990

704

1,694

1,256,406

1,094,670

2,351,076

Total

3,306

2,214

5,520

4,407,470

4,037,047

8,444,517

Age
0-10

M
6.1
(4.3, 8.5)
50.5
(45.3, 56.1)
97.7
(86.6, 109.8)
95.0
(87.3, 103.3)
76.7
(70.8, 83.0)
75.4
(70.3, 80.7)
65.8
63.3, 68.3)

Total
5.6
(4.3, 7.1)
56.1
(52.1, 60.2)
128.5
(118.7, 137.7)
114.8
(108.9, 120.9)
95.6
(91.0, 100.3)
85.2
(81.5, 89.0)
79.4
(77.5, 81.3)

Prevalence per 100,000 (95% CI)*

Age
0-10

Narcolepsy, With Cataplexy Diagnosis
Prevalent Cases

F
5.0
(3.3, 7.2)
61.8
(56.0, 68.0)
154.9
(141.9, 168.8)
132.0
(123.4, 141.0)
112.1
(105.4, 119.1)
93.7
(88.5, 99.2)
91.8
(89.0, 94.7)

Population

F
4.1
(2.6, 6.1)
46.8
(41.7, 52.3)
124.2
(112.5, 136.7)
106.5
(98.8, 114.6)
92.9
(86.8, 99.3)
78.8
(74.0, 83.9)
75.0
(72.5, 77.6)

M
5.3
(3.6, 7.5)
39.0
(34.5, 44.0)
77.2
(67.4, 88.0)
79.2
(72.1, 86.8)
66.0
(60.5, 71.9)
64.3
(59.6, 69.2)
54.8
(52.6, 57.2)

Total
4.7
(3.5, 6.1)
42.9
(39.4, 46.5)
102.5
(94.7, 110.7)
93.8
(88.5, 99.3)
80.4
(76.2, 84.7)
72.1
(68.7, 75.6)
65.4
(63.7, 67.14)

Prevalence per 100,000 (95% CI)*

F
5

M
5

Total
10

F
562,675

M
587,581

Total
1,150,256

11-20

100

78

178

664,926

681,609

1,346,535

21-30

103

59

162

334,993

287,654

622,647

31-40

170

92

262

666,818

579,759

1,246,577

41-50

177

86

263

921,652

805,774

1,727,426

51-65

187

121

308

1,256,406

1,094,670

2,351,076

Total

742

441

1,183

4,407,470

4,037,047

8,444,517

*95% Confidence Interval
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F
0.9
(0.3, 2.1)
15.0
(12.2, 18.3)
30.7
(25.1, 37.3)
25.5
(21.8, 29.6)
19.2
(16.5, 22.2)
14.9
(12.8, 17.2)
16.8
(15.6, 18.1)

M
0.9
(0.3, 1.9)
11.4
(9.0, 14.3)
20.5
(15.6, 26.5)
15.9
(12.8, 19.5)
10.7
(8.5, 13.2)
11.1
(9.2, 13.2)
10.9
(9.9, 12.0)

Total
0.9
(0.4, 1.6)
13.2
(11.3, 15.3)
26.0
(22.2, 30.3)
21.0
(15.5, 23.7)
15.2
(13.4, 17.2)
13.1
(11.7, 14.6)
14.0
(13.2, 14.8)

Table 2.2 – Incidence of Narcolepsy, by Criteria, Age Group, and Gender, 2008-2010
Multiple Sleep Latency Test ± 180 Days of First Narcolepsy Diagnosis*
Narcolepsy, Regardless of Cataplexy Diagnosis
Incident Cases
Population
Incidence per 100,000 per year (95% CI)#
Age
0-10

F
7

M
12

Total
19

F
562,675

M
587,582

Total
1,150,257

11-20

194

165

359

664,934

681,608

1,346,542

21-30

175

86

334,991

287,661

622,652

31-40

279

137

666,819

579,758

1,246,577

41-50

288

154

921,654

805,776

1,727,430

51-65

295

151

1,256,397

1,094,662

2,351,059

Total

1,238

705

4,407,470

4,037,047

8,444,517

261
416
442
446
1,943

Narcolepsy, Without Cataplexy Diagnosis
Incident Cases
Age
0-10

Population

M
0.68
(0.35, 1.19)
8.07
(6.89, 9.40)
9.97
(7.97, 12.31)
7.88
(6.61, 9.31)
6.37
(5.40, 7.46)
4.60
(3.89, 5.39)
5.82
(5.40, 6.27)

Total
0.55
(0.33, 0.86)
8.89
(7.99, 9.86)
13.97
12.33, 15.77)
11.12
(10.08, 12.25)
8.53
(7.75, 9.36)
6.32
(5.75, 6.94)
7.67
(7.33, 8.02)

Incidence per 100,000 per year (95% CI)

F
6

M
10

Total
16

F
562,675

M
587,582

Total
1,150,257

11-20

141

120

261

664,934

681,608

1,346,542

21-30

127

59

186

334,991

287,661

622,652

31-40

207

108

315

666,819

579,758

1,246,577

41-50

242

122

364

921,654

805,776

1,727,430

51-65

250

134

384

1,256,397

1,094,662

2,351,059

Total

973

553

1,526

4,407,470

4,037,047

8,444,517

Narcolepsy, With Cataplexy Diagnosis
Incident Cases

F
0.41
(0.17, 0.85)
9.73
(8.41, 11.27)
17.41
(14.93, 20.19)
13.95
(12.36, 15.68)
10.42
(9.25, 11.69)
7.83
(6.96, 8.77)
9.36
(8.85, 9.90)

Population

F
0.36
(0.13, 0.77)
7.07
(5.95, 8.34)
12.64
(10.54, 15.04)
10.35
(8.99, 11.86)
8.75
(7.68, 9.93)
6.63
(5.84, 7.51)
7.36
(6.90, 7.84)

M
0.57
(0.27, 1.04)
5.87
(4.87, 7.02)
6.84
(5.20, 8.82)
6.21
(5.09, 7.50)
5.05
(4.19, 6.03)
4.08
(3.42, 4.83)
4.57
(4.19, 4.96)

Total
0.46
(0.27, 0.75)
6.46
(5.70, 7.29)
9.96
(8.58, 11.50)
8.42
(7.52, 9.41)
7.02
(6.32, 7.78)
5.44
(4.91, 6.02)
6.02
(5.73, 6.33)

Incidence per 100,000 per year (95% CI)

Age
0-10

F
1

M
2

Total
3

F
562,675

M
587,582

Total
1,150,257

11-20

53

45

98

664,934

681,608

1,346,542

21-30

48

27

75

334,991

287,661

622,652

31-40

72

29

101

666,819

579,758

1,246,577

41-50

46

32

78

921,654

805,776

1,727,430

51-65

45

17

62

1,256,397

1,094,662

2,351,059

Total

265

152

417

4,407,470

4,037,047

8,444,517

F
0.06
(0.00, 0.33)
2.66
(1.99, 3.48)
4.78
(3.52, 6.33)
3.60
(2.82, 4.53)
1.66
(1.22, 2.22)
1.19
(0.87, 1.60)
2.00
(1.77, 2.26)

M
0.11
(0.01, 0.41)
2.20
(1.61, 2.94)
3.13
(2.06, 4.55)
1.67
(1.12, 2.39)
1.32
(0.91, 1.87)
0.52
(0.30, 0.83)
1.26
(1.06, 1.47)

Total
0.09
(0.02, 0.25)
2.43
(1.97, 2.96)
4.02
(3.16, 5.03)
2.70
(2.20, 3.28)
1.51
(1.19, 1.88)
0.88
(0.67, 1.13)
1.65
(1.49, 1.81)

Multiple Sleep Latency Test ≤180 Days Before or ≤30 Days After First Narcolepsy Diagnosis*
Narcolepsy, Regardless of Cataplexy Diagnosis
Incident Cases
Population
Incidence per 100,000 per year (95% CI)
Age
0-10

F
7

M
12

Total
19

F
562,675

M
587,582

Total
1,150,257

65

F
0.41
(0.17, 0.85)

M
0.68
(0.35, 1.19)

Total
0.55
(0.33, 0.86)

Table 2.2 – Incidence of Narcolepsy, by Criteria, Age Group, and Gender, 2008-2010, continued
11-20

180

153

333

664,935

681,608

1,346,543

9.02
(7.75, 10.44)

7.48
(6.34, 8.77)

8.24
(7.38, 9.18)

21-30

155

77

232

334,990

287,661

622,651

31-40

263

126

389

666,819

579,758

1,246,577

41-50

267

145

412

921,654

805,776

1,727,430

51-65

276

145

421

1,256,397

1,094,662

2,351,059

Total

1,148

658

1,806

4,407,470

4,037,047

8,444,517

15.42
(13.09, 18.05)
13.15
(11.61, 14.84)
9.66
(8.53, 10.89)
7.32
(6.48, 8.24)
8.68
(8.19, 9.20)

8.92
(7.04, 11.15)
7.24
(6.03, 8.63)
6.00
(5.06, 7.06)
4.42
(3.73, 5.20)
5.43
(5.03, 5.86)

12.42
(10.87, 14.12)
10.40
(9.39, 11.49)
7.95
(7.20, 8.76)
5.97
(5.41, 6.57)
7.13
(6.80, 7.47)

Narcolepsy, Without Cataplexy Diagnosis
Incident Cases
Age
0-10

Population

Incidence per 100,000 per year (95% CI)

F
6

M
10

Total
16

F
562,675

M
587,582

Total
1,150,257

11-20

132

110

242

664,935

681,608

1,346,543

21-30

113

53

166

334,990

287,661

622,651

31-40

198

100

298

666,819

579,758

1,246,577

41-50

227

117

344

921,654

805,776

1,727,430

51-65

236

129

365

1,256,397

1,094,662

2,351,059

Total

912

519

1,431

4,407,470

4,037,047

8,444,517

Narcolepsy, With Cataplexy Diagnosis
Incident Cases

Population

F
0.36
(0.13, 0.77)
6.62
(5.54, 7.85)
11.24
(9.27, 13.52)
9.90
(8.57, 11.38)
8.21
(7.18, 9.35)
6.26
(5.49, 7.11)
6.90
(6.46, 7.36)

M
0.57
(0.27, 1.04)
5.38
(4.42, 6.48)
6.14
(4.60, 8.03)
5.75
(4.68, 6.99)
4.84
(4.00, 5.80)
3.93
(3.28, 4.67)
4.29
(3.69, 4.67)

Total
0.46
(0.27, 0.75)
5.99
(5.26, 6.79)
8.89
(7.59, 10.35)
7.97
(7.09, 8.93)
6.64
(5.96, 7.38)
5.17
(4.66, 5.73)
5.65
(5.36, 5.95)

Incidence per 100,000 per year (95% CI)

Age
0-10

F
1

M
2

Total
3

F
562,675

M
587,582

Total
1,150,257

11-20

48

43

91

664,935

681,608

1,346,543

21-30

42

24

66

334,990

287,661

622,651

31-40

65

26

91

666,819

579,758

1,246,577

41-50

40

28

68

921,654

805,776

1,727,430

51-65

40

16

56

1,256,397

1,094,662

2,351,059

Total

236

139

375

4,407,470

4,037,047

8,444,517

F
0.06
(0.00, 0.33)
2.41
(1.77, 3.19)
4.18
(3.01, 5.65)
3.25
(2.51, 4.14)
1.45
(1.03, 1.97)
1.06
(0.76, 1.45)
1.78
(1.56, 2.03)

M
0.11
(0.01, 0.41)
2.10
(1.52, 2.83)
2.78
(1.78, 4.14)
1.49
(0.98, 2.19)
1.16
(0.77, 1.67)
0.49
(0.28, 0.79)
1.15
(0.96, 1.36)

Total
0.09
(0.02, 0.25)
2.25
(1.81, 2.77)
3.53
(2.73, 4.50)
2.43
(1.96, 2.99)
1.31
(1.02, 1.66)
0.79
(0.60, 1.03)
1.48
(1.33, 1.64)

Multiple Sleep Latency Test ≤180 Days Before First Narcolepsy Diagnosis
Narcolepsy, Regardless of Cataplexy Diagnosis
Incident Cases
Population
Incidence per 100,000 per year (95% CI)
Age
0-10

F
7

M
7

Total
14

F
562,675

M
587,582

Total
1,150,257

11-20

106

103

209

664,937

681,610

1,346,547

21-30

94

51

145

334,988

287,659

622,647

31-40

181

87

268

666,819

579,761

1,246,580

41-50

180

100

280

921,655

805,774

1,727,429

66

F
0.41
(0.17, 0.85)
5.31
(4.35, 6.43)
9.35
(7.56, 11.45)
9.05
(7.78, 10.47)
6.51
(5.59, 7.53)

M
0.40
(0.16, 0.82)
5.04
(4.11, 6.11)
5.91
(4.40, 7.77)
5.00
(4.01, 6.17)
4.14
(3.37, 5.03)

Total
0.41
(0.22, 0.68)
5.17
(4.50, 5.92)
7.76
(6.55, 9.13)
7.17
(6.33, 8.08)
5.40
(4.79, 6.07)

Table 2.2 – Incidence of Narcolepsy, by Criteria, Age Group, and Gender, 2008-2010, continued
51-65

205

112

317

1,256,396

1,094,661

2,351,057

Total

773

460

1,233

4,407,470

4,037,047

8,444,517

Narcolepsy, Without Cataplexy Diagnosis
Incident Cases

Population

3.41
(2.81, 4.10)
3.80
(3.46, 4.16)

4.49
(4.01, 5.02)
4.87
(4.60, 5.15)

Incidence per 100,000 per year (95% CI)

Age
0-10

F
6

M
5

Total
11

F
562,675

M
587,582

Total
1,150,257

11-20

83

76

159

664,937

681,610

1,346,547

21-30

72

39

111

334,988

287,659

622,647

31-40

140

68

208

666,819

579,761

1,246,580

41-50

157

85

242

921,655

805,774

1,727,429

51-65

181

103

284

1,256,396

1,094,661

2,351,057

Total

639

376

1,015

4,407,470

4,037,047

8,444,517

Narcolepsy, With Cataplexy Diagnosis
Incident Cases

5.44
(4.72, 6.24)
5.85
(5.44, 6.27)

Population

F
0.36
(0.13, 0.77)
4.16
(3.31, 5.16)
7.16
(5.61, 9.02)
7.00
(5.89, 8.26)
5.68
(4.82, 6.64)
4.80
(4.13, 5.55)
4.83
(4.47, 5.22)

M
0.28
(0.09, 0.66)
3.72
(2.93, 4.65)
4.52
(3.21, 6.18)
3.91
(3.04, 4.96)
3.52
(2.81, 4.35)
3.14
(2.56, 3.80)
3.10
(2.80, 3.43)

Total
0.32
(0.16, 0.57)
3.94
(3.35, 4.60)
5.94
(4.89, 7.16)
5.56
(4.83, 6.37)
4.67
(4.10, 5.30)
4.03
(3.57, 4.52)
4.01
(3.76, 4.26)

Incidence per 100,000 per year (95% CI)

Age
0-10

F
1

M
2

Total
3

F
562,675

M
587,582

Total
1,150,257

11-20

23

27

50

664,937

681,610

1,346,547

21-30

22

12

34

334,988

287,659

622,647

31-40

41

19

60

666,819

579,761

1,246,580

41-50

23

15

38

921,655

805,774

1,727,429

51-65

24

9

33

1,256,396

1,094,661

2,351,057

Total

134

84

218

4,407,470

4,037,047

8,444,517

F
0.06
(0.00, 0.33)
1.15
(0.73, 1.73)
2.19
(1.37, 3.31)
2.05
(1.47, 2.78)
0.83
(0.53, 1.25)
0.64
(0.41, 0.95)
1.01
(0.85, 1.20)

M
0.11
(0.01, 0.41)
1.32
(0.87, 1.92)
1.39
(0.72, 2.43)
1.09
(0.66, 1.71)
0.62
(0.35, 1.02)
0.27
(0.13, 0.52)
0.69
(0.55, 0.86)

Total
0.09
(0.02, 0.25)
1.24
(0.92, 1.63)
1.82
(1.26, 2.54)
1.60
(1.22, 2.07)
0.73
(0.52, 1.01)
0.47
(0.32, 0.66)
0.86
(0.75, 0.98)

* a follow-up diagnosis for narcolepsy must be observed for cases in which the multiple sleep latency test is recorded after the
first narcolepsy diagnosis
# 95% Confidence Interval
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Table 2.3 – Incidence of Narcolepsy, by Criteria, 3 Year Age Groupings (11 to 40 Year Olds), 2008-2010
Multiple Sleep Latency Test ± 180 Days of First Narcolepsy Diagnosis*

Age

Pop

11-13
14-16
17-19
20-22
23-25
26-28
29-31
32-34
35-37
38-40

421,688
459,542
369,885
189,668
129,382
218,391
281,408
327,004
382,833
435,970

Age

11-13
14-16
17-19
20-22
23-25
26-28
29-31
32-34
35-37
38-40

Narcolepsy, Regardless of
Cataplexy Diagnosis
Cases
Incidence per
100,000 per year
(95% CI) #
41
104
167
94
51
89
100
116
142
132

3.24
7.54
15.05
16.52
13.14
13.58
11.85
11.82
12.36
10.09

(2.33, 4.40)
(6.16, 9.14)
(12.85, 17.51)
(13.35, 20.22)
(9.78, 17.27)
(10.91, 16.72)
(9.64, 14.41)
(9.77, 14.18)
(10.41, 14.57)
(8.44, 11.97)

Narcolepsy, Without Cataplexy
Diagnosis
Cases
Incidence per
100,000 per year
(95% CI)
28
73
129
65
35
60
76
87
108
101

2.21
5.30
11.63
11.42
9.02
9.16
9.00
8.87
9.40
7.72

(1.47, 3.20)
(4.15, 6.66)
(9.71, 13.81)
(8.82, 14.56)
(6.28, 12.54)
(6.99, 11.79)
(7.09, 11.27)
(7.10, 10.94)
(7.71, 11.35)
(6.29, 9.38)

Narcolepsy, With Cataplexy
Diagnosis
Cases
Incidence per
100,000 per year
(95% CI)
13
31
38
29
16
29
24
29
34
31

1.03
2.25
3.42
5.10
4.12
4.43
2.84
2.96
2.96
2.37

(0.55, 1.76)
(1.53, 3.19)
(2.42, 4.70)
(3.41, 7.32)
(2.36, 6.69)
(2.96, 6.36)
(1.82, 4.23)
(1.98, 4.25)
(2.05, 4.14)
(1.61, 3.36)

Multiple Sleep Latency Test ≤180 Days Before or ≤30 Days After First Narcolepsy Diagnosis*
Narcolepsy, Regardless of
Narcolepsy, Without Cataplexy
Narcolepsy, With Cataplexy
Cataplexy Diagnosis
Diagnosis
Diagnosis
Pop
Cases
Incidence per
Cases
Incidence per
Cases
Incidence per
100,000 per year
100,000 per year
100,000 per year
(95% CI)
(95% CI)
(95% CI)
421,688
459,542
369,885
189,668
129,382
218,392
281,407
327,005
382,833
435,969

Age

Pop

11-13
14-16
17-19
20-22
23-25
26-28
29-31
32-34
35-37
38-40

421,689
459,546
369,881
189,667
129,383
218,392
281,410
327,002
382,836
435,968

38
95
154
91
45
82
82
108
136
123

3.00
6.89
13.88
15.99
11.59
12.52
9.71
11.01
11.84
9.40

(2.13, 4.12)
(5.58, 8.42)
(11.77, 16.25)
(12.88, 19.63)
(8.46, 15.51)
(9.95, 15.53)
(7.73, 12.06)
(9.03, 13.29)
(9.94, 14.01)
(7.82, 11.22)

26
67
119
64
31
55
61
83
104
96

2.06
4.86
10.72
11.25
7.99
8.39
7.23
8.46
9.06
7.34

(1.34, 3.01)
(3.77, 6.17)
(8.88, 12.83)
(8.66, 14.36)
(5.43, 11.34)
(6.32, 10.93)
(5.63, 9.28)
(6.74, 10.49)
(7.47, 10.97)
(5.95, 8.96)

12
28
35
27
14
27
21
25
32
27

0.95
2.03
3.15
4.75
3.61
4.12
2.49
2.55
2.79
2.06

(0.49, 1.66)
(1.35, 2.94)
(2.20, 4.39)
(3.13, 6.90)
(1.97, 6.05)
(2.72, 6.00)
(1.54, 3.80)
(1.65, 3.76)
(1.91, 3.93)
(1.36, 3.00)

Multiple Sleep Latency Test ≤180 Days Before First Narcolepsy Diagnosis
Narcolepsy, Regardless of
Narcolepsy, Without Cataplexy
Narcolepsy, With Cataplexy
Cataplexy Diagnosis
Diagnosis
Diagnosis
Cases
Incidence per
Cases
Incidence per
Cases
Incidence per
100,000 per year
100,000 per year
100,000 per year
(95% CI)
(95% CI)
(95% CI)
17
61
100
59
26
49
59
74
92
85

1.34
4.42
9.01
10.37
6.70
7.48
6.99
7.54
8.01
6.50

(0.78, 2.15)
(3.38, 5.68)
(7.33, 10.96)
(7.89, 13.37)
(4.38, 9.81)
(5.53, 9.89)
(5.32, 9.01)
(5.92, 9.47)
(6.46, 9.82)
(5.19, 8.04)

12
45
82
44
18
35
47
55
70
70

0.95
3.26
7.39
7.73
4.64
5.34
5.57
5.61
6.09
5.35

(0.49, 1.66)
(2.38, 4.37)
(5.88, 9.17)
(5.62, 10.38)
(2.75, 7.33)
(3.72, 7.43)
(4.09, 7.40)
(4.22, 7.30)
(4.75, 7.70)
(4.17, 6.76)

5
16
18
15
8
14
12
19
22
15

0.40
1.16
1.62
2.64
2.06
2.14
1.42
1.94
1.92
1.15

(0.13, 0.92)
(0.66, 1.88)
(0.96, 2.56)
(1.48, 4.35)
(0.89, 4.06)
(1.17, 3.59)
(0.73, 2.48)
(1.17, 3.02)
(1.20, 2.90)
(0.64, 1.89)

* a follow-up diagnosis for narcolepsy must be observed for cases in which the multiple sleep latency test is recorded after
the first narcolepsy diagnosis
# 95% Confidence Interval
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Table 2.4 – Prevalence of Narcolepsy, by U.S. Region, 2008-2010
Narcolepsy, Regardless of Cataplexy Diagnosis
Region
Prevalent Cases
Northeast
673
North Central
2,361
South
2,819
West
829
Unknown
21

Population
1,158,701
2,088,802
3,330,637
1,837,049
29,328

Prevalence per 100,000 (95% CI)*
58.08
(53.78, 62.64)
113.03
(108.52, 117.68)
84.64
(81.54, 87.82)
45.13
(42.11, 48.31)
71.60
(44.33, 109.43)

Narcolepsy, Without Cataplexy Diagnosis
Region
Prevalent Cases
Northeast
540
North Central
1,996
South
2,302
West
666
Unknown
16

Population
1,158,701
2,088,802
3,330,637
1,837,049
29,328

Prevalence per 100,000 (95% CI)
46.60
(42.76, 50.70)
95.56
(91.41, 99.84)
69.12
(66.32, 72.00)
36.25
(33.55, 39.11)
54.56
(31.19, 88.58)

Narcolepsy, With Cataplexy Diagnosis
Region
Prevalent Cases
Northeast
133
North Central
365
South
517
West
163
Unknown
5

Population
1,158,701
2,088,802
3,330,637
1,837,049
29,328

Prevalence per 100,000 (95% CI)
11.48
(9.61, 13.6)
17.47
(15.73, 19.36)
15.52
(14.21, 16.82)
8.87
(7.56, 10.34)
17.05
(5.54, 39.78)

*

95% Confidence Interval
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Table 2.5 – Incidence of Narcolepsy, by Criteria and U.S. Region, 2008-2010
Multiple Sleep Latency Test ± 180 Days of First Narcolepsy Diagnosis*
Narcolepsy, Regardless of
Cataplexy Diagnosis
Region

Population

Cases

Northeast
North Central
South
West
Unknown

1,158,701
2,088,801
3,330,638
1,837,049
29,328

215
796
772
153
7

Incidence per
100,000 per year
(95% CI)#
6.19 (5.39, 7.07)
12.70 (11.84, 13.62)
7.73 (7.19, 8.29)
2.78 (2.35, 3.25)
7.96 (3.20, 16.39)

Narcolepsy, Without Cataplexy
Diagnosis

Narcolepsy, With Cataplexy
Diagnosis

Cases

Cases

166
653
587
115
5

Incidence per
100,000 per year
(95% CI)
4.78 (4.08, 5.56)
10.42 (9.64, 11.25)
5.87 (5.41, 6.37)
2.09 (1.72, 2.50)
5.68 (1.85, 13.26)

49
143
185
38
2

Incidence per
100,000 per year
(95% CI)
1.41 (1.04, 1.86)
2.28 (1.92, 2.69)
1.85 (1.59, 2.14)
0.69 (0.49, 0.95)
2.27 (0.28, 8.21)

Multiple Sleep Latency Test ≤180 Days Before or ≤30 Days After First Narcolepsy Diagnosis*
Narcolepsy, Regardless of
Cataplexy Diagnosis
Region

Population

Cases

Northeast
North Central
South
West
Unknown

1,158,701
2,088,801
3,330,638
1,837,049
29,328

193
742
729
135
7

Incidence per
100,000 per year
(95% CI)
5.55 (4.80, 6.39)
11.84 (11.00, 12.72)
7.30 (6.78, 7.85)
2.45 (2.05, 2.90)
7.96 (3.20, 16.39)

Narcolepsy, Without Cataplexy
Diagnosis

Narcolepsy, With Cataplexy
Diagnosis

Cases

Cases

152
609
563
102
5

Incidence per
100,000 per year
(95% CI)
4.37 (3.71, 5.13)
9.72 (8.96, 10.52)
5.63 (5.18, 6.12)
1.85 (1.51, 2.25)
5.68 (1.85, 13.26)

41
133
166
33
2

Incidence per
100,000 per year
(95% CI)
1.18 (0.85, 1.60)
2.12 (1.78, 2.52)
1.66 (1.42, 1.93)
0.60 (0.41, 0.84)
2.27 (0.28, 8.21)

Multiple Sleep Latency Test ≤180 Days Before First Narcolepsy Diagnosis
Narcolepsy, Regardless of
Cataplexy Diagnosis
Region

Population

Narcolepsy, Without Cataplexy
Diagnosis

Cases

Narcolepsy, With Cataplexy
Diagnosis

Incidence per
Cases
Incidence per
Cases
Incidence per
100,000 per year
100,000 per year
100,000 per year
(95% CI)
(95% CI)
(95% CI)
Northeast
1,158,701
139
4.00 (3.36, 4.72)
111
3.19 (2.63, 3.85)
28
0.81 (0.54, 1.16)
North Central
2,088,801
500
7.98 (7.29, 8.71)
430
6.86 (6.23, 7.54)
70
1.12 (0.87, 1.41)
South
3,330,638
491
4.91 (4.49, 5.37)
389
3.89 (3.52, 4.30)
102
1.02 (0.83, 1.24)
West
1,837,049
99
1.80 (1.46, 2.19)
81
1.47 (1.17, 1.83)
18
0.33 (0.19, 0.52)
Unknown
29,328
4
4.55 (1.24, 11.64)
4
4.55 (1.24, 11.64)
0
0.00 (0, 0)
* a follow-up diagnosis for narcolepsy must be observed for cases in which the multiple sleep latency test is recorded after the first
narcolepsy diagnosis
#
95% Confidence Interval
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CHAPTER THREE
MANUSCRIPT 2: RESPIRATORY INFECTIONS AND INCIDENT NARCOLEPSY IN A
U.S. HEALTH CARE CLAIMS DATABASE, 2008-2010
Introduction
Narcolepsy is a chronic neurological disorder characterized primarily by excessive daytime
sleepiness (EDS) and, in many cases, cataplexy.1;2;4;167 Cataplexy is characterized by one or more
sudden short term (<2 minutes) losses of muscle tone (often due to an emotional trigger), yet
consciousness is retained.167 An increase in mortality, physical ailments, and psychiatric comorbid
conditions have been associated with narcolepsy, compared to the general population.5-10 Due to
these adverse experiences, narcolepsy patients experience approximately a doubling of various
annual healthcare related facility visits, transactions, and costs comparatively.11
Estimates of the incidence and prevalence of narcolepsy have greatly changed over time and
across epidemiological studies, yet the condition continues to be considered a rare sleep
disorder.1;1;12-16;21;43;189

For example, the overall incidence of narcolepsy found in the few

investigations has ranged approximately from 0.74 to over 27 cases/100,000 persons per
year.18;20;189 These assessments have been difficult to conduct and few large epidemiological
studies exist.12-20;189 Additionally, exposures and potential triggers for development of narcolepsy
have been difficult to evaluate, due in part to the low rate of the disease in the general population.
Few specific infections have actually been investigated regarding the potential to induce
incident narcolepsy.90;91 During the time period of our study, an increase in narcolepsy risk was
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linked to adjuvanted influenza vaccines in various countries.55;65-78;170 These adjuvanted vaccines
were not used in the U.S. As a result of the discovered link between adjuvanted influenza
vaccination and narcolepsy development, influenza appears to be the most studied infection
worldwide, with conflicting results.71;74;97-99 In a case-control study of a different infection type,
Streptococcus pyogenes, an increased risk for narcolepsy occurred within 3 years of infection.95
However, no large U.S. epidemiological studies are available investigating the potential
relationship between various prior respiratory infections and incident narcolepsy.
Because of these limitations and the negative impact that narcolepsy can have on the patient
population, we conducted this case-control study of the relationship between incident narcolepsy
and prior respiratory infections using a large U.S. health care claims database. Using a claims
database with sufficient population size, wide age distributions, and expanded U.S. regional
coverage allows for more precise estimates for a disease with a predicted low incidence, such as
narcolepsy.
Methods
Study Design
We conducted a case-control study to estimate the potential risk of developing narcolepsy
following respiratory infection using the Truven Health MarketScan Commercial Dissertation
Database (THMCDD) for the period January 1, 2008 to December 31, 2010. The THMCDD
encompasses approximately 100 private-sector health insurers, covering over 18 million people
under the age of 66, and more than a billion observations/records in the U.S. The THMCDD
captures person-specific information related to various inpatient, outpatient, and prescription drug
claims. This includes both diagnoses and procedure claims. A unique enrollee identification
number is assigned to each individual. These enrollees are “de-identified” as the database did not
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contain personal identifying information. This is in compliance with the Health Insurance
Portability and Accountability Act. This study was reviewed by the University of South Florida
Institutional Review Board (IRB) who determined it exempt from further review.

Study Population
The eligible study population was all enrollees in the THMCDD, 65 years of age and younger,
and continuously enrolled for years 2008 to 2010. Continuously enrolled individuals were
required to have enrollment during each month for the entire 36 month period. Cases and controls
were then selected according to certain criteria.
Cases and Controls
Incident cases of narcolepsy, with or without cataplexy, were identified using the International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM = 347.0, 347.00,
347.01, 347.1, 347.10, or 347.11). The shortened codes ICD-9-CM 347.0 and 347.1 were included
in case claims were made in which the cataplexy status (defined by the fifth digit of the code:
0=without cataplexy, 1=with cataplexy) was not identified for any reason. Both primary (ICD-9CM 347.00 and 347.01; identified by the fourth digit “0”) and secondary (ICD-9-CM 347.10 and
347.11; identified by the fourth digit “1”) were included in the analyses.
To be included as an incident case, first, enrollees had to have a claim for a polysomnography
(PSG) (CPT 95808, 95810, 95811, or ICD-9-CM 89.17) within 2 days of a multiple sleep latency
test (MSLT) (CPT 95805 or ICD-9-CM 89.18). After obtaining the enrollees that met the PSG
and MSLT criteria, incident cases were determined using two definitions (ND1 and ND2) (Table
3.1): 1.) MSLT claim within 180 days, before or after, of the first narcolepsy claim; a follow-up
diagnosis for narcolepsy must be observed for cases in which the multiple sleep latency test is
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recorded after the first narcolepsy diagnosis (ND1), 2.) MSLT claim within 180 days before the
first narcolepsy claim (ND2). Two incidence criteria were employed to account for possible
differences in temporality or delays in reporting procedures, diagnosis claims, or follow-up visits.
For the current study, incident cases with the first narcolepsy diagnosis occurring July 1, 2009
through December 31, 2010 were included. The date of first diagnosis was considered the index
date.
In order to create a control sample matched for the infection lookback time period, forty
enrollees without narcolepsy were randomly chosen for each case and assigned the index date of
that case. No other matching was used. Additionally, enrollees were only eligible to be a control
if they did not have a diagnosis for narcolepsy during the entire 2008 to 2010 time period.
Respiratory Infections
The respiratory infections were generally categorized by ICD-9-CM groupings (Table 3.2).
The groupings were chosen based on clinical and research experience by the authors and limited
literature noting a possible association between certain respiratory infections and development of
autoimmune reactions and narcolepsy.90-94;96-99
Cases and controls were considered to be positive for a respiratory infection if they were
diagnosed with any of the qualifying ICD-9-CM codes during one of four periods prior to the index
date. Varying lookback time periods (Table 3.1) were used to account for potential differences in
delay to development of narcolepsy signs and symptoms, due to acute infections, as previously
noted in prior studies.95;97 The four time periods were: 1.) infection occurring within 18 months
prior to index date (P1), 2.) infection occurring 1 year prior to index date (P2), 3.) infection
occurring 3 to 15 months prior to index date (P3), and 4.) infection occurring 6 to 18 months prior
to index date (P4). Multiple recordings of the same infection code Group for a single patient were
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considered one infection. If a patient was considered to have more than one eligible infection, and
the ICD-9-CM codes were from different infection Groups, that patient was counted once for each
Group.
Demographic Measures
Age at each year was available, but date of birth was not. The age of a case subject was
considered the age at which the enrollee met the criteria for narcolepsy. The age of a control was
defined as the age at the mid-year of the enrollment period, 2009. Additionally, gender (male or
female) and U.S. region (northeast, north central, south, west, and unknown) were noted for each
enrollee (Table 3.3).
Statistical Analysis
The demographical characteristics of subjects were tabulated according to the two definitions
of incident narcolepsy (ND1 and ND2). Differences between cases and controls for categorical
variables (sex and geographical region) were assessed via Chi-square analysis. Age (continuous
variable) differences between cases and controls were calculated using t-test.
Both crude and adjusted odds ratios (OR) with 95% Confidence Intervals (CI) were calculated
to assess the potential relationship for prior respiratory infection and development of narcolepsy.
For the crude ORs, logistic regression was used and included a factor for the index date. The
adjusted ORs (aOR) were calculated using logistic regression with factors for index date, sex,
geographical region, and age. All three available demographic factors (sex, geographic region,
age) were used in the model since our previous research has noted their impacts on narcolepsy
estimates.189 For the overall incident cases, regardless of sex, ORs were calculated for all
respiratory infection groups (1-9), the four infection assessment periods prior to the index dates,
and by both ND1 (Table 3.4) and ND2 (Table 3.5). Even though the THMCDD is a large database,
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the potential for small cell numbers (small infection counts) for either cases or controls existed.
Therefore, in order to avoid highly unstable estimates, it was determined a priori that for the overall
incident narcolepsy and respiratory infection assessments (Tables 3.4 and 3.5), any ORs associated
with respiratory infection counts of either “0” or “1” would be considered to have an indeterminate
OR.
The potential relationship of respiratory infections and development of narcolepsy was
additionally assessed separately for males and females (Table 3.6). For a respiratory infection
Group to qualify for evaluation by sex, it was determined a priori that the Group must be recorded
as diagnosed in at least 10 cases and 10 controls for all infection time periods (P1-P4) for both
overall ND1 (Table 3.4) and ND2 (Table 3.5) assessments. The logistic regression used to
calculate crude ORs included a factor for the index date, while the model used for the adjusted
ORs (aOR) included factors for index date, geographical region, and age. These evaluations also
stratified by infection period prior to index date (P1-P4), ND1, and ND2.
ORs were considered statistically significant if the 95% CI did not include 1.00. All analyses
were performed using SAS software version 9.4 (SAS Institute, Inc.).
Results
In the THMCDD, there were 8,444,517 continuous enrollees for the period 2008-2010. Table
3.3 provides demographics and characteristics for cases and controls by ND1 and ND2.
Differences for age, sex and geographical region were all statistically significant for both ND1 and
ND2 definitions.
Overall ND1 (MSLT ± 180 Days of First Narcolepsy Diagnosis) Assessment by Infection Period
For ND1, infection Groups 5 (acute respiratory infections), 7 (bacterial pneumonias), 8
(pneumonias due to other organisms or unspecified), and 9 (influenzas) (See Table 3.2) were
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associated with elevated crude and adjusted ORs for all four infection assessment periods (Table
3.4). Statistically significant adjusted ORs were obtained during all infection assessment periods
for Group 5 (P1 aOR=1.63, 95% CI 1.43 to 1.85; P2 aOR=1.60, 95% CI 1.40 to 1.83; P3
aOR=1.73, 95% CI 1.52 to 1.98; P4 aOR=1.60, 95% CI 1.40 to 1.83) and Group 9 (P1 aOR=1.49,
95% CI 1.06 to 2.12; P2 aOR=1.51, 95% CI 1.01 to 2.25; P3 aOR=1.53, 95% CI 1.04 to 2.25; P4
aOR=1.55, 95% CI 1.04 to 2.31). Group 8 was associated with statistically significant adjusted
ORs during P1 (aOR=1.69, 95% CI 1.17 to 2.46), P2 (aOR=1.73, 95% CI 1.13 to 2.64), and P4
(aOR=1.60, 95% CI 1.02 to 2.53). Group 3 (streptococcal sore throat and scarlet fever) crude and
adjusted ORs were approximately 1.0 for P1 and P4, and lower during P2 and P3. These lower
ORs were not statistically significant. Group 7 infection ORs were elevated for all calculations,
even doubling during P1 and approaching statistical significance. However, none of these
estimates were statistically significant and few Group 7 infections occurred in the narcolepsy
population.
Infection Groups 1, (tuberculosis), 2 (zoonotic and other bacterial infections), 4 (mycoses,
helminthiases, and other infectious and parasitic diseases), and 6 (viral pneumonia) occurred in
few patients and risk assessments were indeterminate.
Overall ND2 (MSLT ≤180 Days Before First Narcolepsy Diagnosis) Assessment by Infection
Period
For ND2, infection Groups 5 (acute respiratory infections), 7 (bacterial pneumonias), 8
(pneumonias due to other organisms or unspecified), and 9 (influenzas) (See Table 3.2) were again
associated with elevated crude and adjusted ORs for all four infection assessment periods (Table
3.5). Statistically significant adjusted ORs were obtained during all infection assessment periods
for Group 5 (P1 aOR=1.77, 95% CI 1.52 to 2.08; P2 aOR=1.63, 95% CI 1.38 to 1.93; P3
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aOR=1.85, 95% CI 1.57 to 2.19; P4 aOR=1.71, 95% CI 1.45 to 2.02) and Group 9 (P1 aOR=1.67,
95% CI 1.08 to 2.56; P2 aOR=1.70, 95% CI 1.03 to 2.79; P3 aOR=1.77, 95% CI 1.10 to 2.84; P4
aOR=1.66, 95% CI 1.01 to 2.72). Infection Groups 7 and 8 both had statistically significant
adjusted ORs during P1 (Group 7: aOR=2.87, 95% CI 1.24 to 6.63; Group 8: aOR=1.68, 95% CI
1.04 to 2.72) and P2 (Group 7: aOR=2.84, 95% CI 1.02 to 7.90; Group 8: aOR=1.77, 95% CI 1.03
to 3.05). Although elevated, Groups 7 and 8 were not associated with statistically significant ORs
during P3 or P4. Group 3 (streptococcal sore throat and scarlet fever) crude and adjusted ORs
were increased for P1 and P4, and below 1.0 during P2 and P3. None of the Group 3 ORs were
statistically significant.
For ND2, infection Groups 1(tuberculosis), 2 (zoonotic and other bacterial infections), 4
(mycoses, helminthiases, and other infectious and parasitic diseases), and 6 (viral pneumonia)
occurred in few patients and risk assessments were indeterminate.
Assessment by Sex: ND1 (MSLT ± 180 Days of First Narcolepsy Diagnosis) by Infection Period
Infection Groups 3 (streptococcal sore throat and scarlet fever), 5 (acute respiratory
infections), 8 (pneumonias due to other organisms or unspecified), and 9 (influenzas) were all
observed to have been diagnosed in at least 10 cases and 10 controls for all infection time periods
(P1-P4) for both overall ND1 (Table 3.4) and ND2 (Table 3.5) assessments. Therefore, these 4
infection Groups were analyzed for males and female separately (Table 3.6). For narcolepsy
diagnosis criteria ND1, Group 3 infection ORs were greater for females than males. However,
ORs were all approximately 1.0 (females: P1, P3, P4; males: P4) or lower. ORs for females and
males for Group 5 infections were elevated for all infection assessment periods. Additionally all
were statistically significant, except for the estimate for males during P4 (aOR=1.23, 95% CI 0.96
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to 1.57). Female ORs were notably greater during P3 and P4 (aOR=1.93, 95% CI 1.65 to 2.27 and
aOR=1.81, 95% CI 1.54 to 2.13, respectively).
Analysis of Group 8 infections in males and females displayed alternating patterns. Males
had greater ORs during P1 (aOR=1.92, 95% CI 1.04 to 3.55) and P4 (aOR=2.01, 95% CI 0.98 to
4.12). Females displayed greater ORs during P2 (aOR=1.92, 95% CI 1.17 to 3.16) and P3
(aOR=1.83, 95% CI 1.09 to 3.05). Although all Group 9 infections were elevated for both males
and females, with some approaching significance, only infections during P3 in females were
associated with a statistically significant elevation (aOR=1.67, 95% CI 1.05 to 2.65).
Assessment by Sex: ND2 (MSLT ≤180 Days Before First Narcolepsy Diagnosis) by Infection
Period
For the narcolepsy diagnosis criteria ND2, Group 3 (streptococcal sore throat and scarlet
fever) infection ORs either well below 1.0 or indeterminate, due to few infections (Table 3.5).
However, females were associated with ORs well above 1.0, with interval P1 being significant
(aOR=1.74, 95% CI 1.08 to 2.80) and P4 approaching significance (aOR=1.70, 95% CI 0.97 to
2.96) (Table 3.6). For Group 5 (acute respiratory infections), ORs for P1-P4 were all elevated for
males and approached statistical significance. For females, Group 5 infection ORs were doubled
in 3 of 4 infection periods and all were statistically significant (P1 aOR=1.96, 95% CI 1.61 to 2.39;
P2 aOR=1.78, 95% CI 1.46 to 2.18; P3 aOR=2.16, 95% CI 1.77 to 2.63; P4 aOR=2.00, 95% CI
1.63 to 2.44). Additionally all were statistically significant, except for the estimate for males
during P4 (aOR=1.23, 95% CI 0.96 to 1.57). Female ORs were notably greater during P3 and P4
(aOR=1.93, 95% CI 1.65 to 2.27 and aOR=1.81, 95% CI 1.54 to 2.13, respectively).
Analysis of Group 8 (pneumonias due to other organisms or unspecified), and 9 (influenzas)
infections in males and females again showed alternating patterns.
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Males had statistically

significant more than doubling of Group 8 infections during P1 and P4 (aOR=2.33, 95% CI 1.13
to 4.80; aOR=2.51, 95% CI 1.09 to 5.77, respectively), while for females the estimate only
approached significance in P2 (aOR=1.88, 95% CI 0.98 to 3.59). For Group 9 infections, ORs in
males approached statistical significance during P1 and P4 (aOR=1.94, 95% CI 0.97 to 3.86;
aOR=2.06, 95% CI 0.95 to 4.49, respectively). In females, Group 9 infections were statistically
significant during P3 (aOR=1.82, 95% CI 1.02 to 3.23).
Discussion
In this case-control study, we found trends for statistically significant increases in ORs for
certain types of respiratory infections preceding incident narcolepsy, compared to controls. For
both crude and adjusted models, Group 5 (acute respiratory infections, e.g. nasopharyngitis,
sinusitis), Group 8 (e.g. pneumonia due to other specified organism, pneumonia in infectious
diseases classified elsewhere, bronchopneumonia), and Group 9 (influenzas), ORs were
consistently greater than 1.00 for both incident narcolepsy criteria (ND1: MSLT ± 180 Days of
First Narcolepsy Diagnosis and ND2: MSLT ≤180 Days Before First Narcolepsy Diagnosis). In
fact, acute respiratory infections and influenza were significantly associated with incident
narcolepsy for both ND1 and ND2 for the infection periods P3 and P4. These assessment periods
required a delay in time between infection period and incident narcolepsy diagnosis. Infection
Groups 1 (tuberculosis), 2 (zoonotic and other bacterial infections), 4 (mycoses, helminthiases,
and other infectious and parasitic diseases), and 6 (viral pneumonia) were observed in very few
patients and were considered too few for assessment.
In the assessment of the respiratory infection Groups (3, 5, 8, 9) by sex, females generally had
higher aORs estimates than males. Interestingly, for both ND1 and ND2 during the infection
periods P3 (infection occurring 3 to 15 months prior to index date) and P4 (infection occurring 6
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to 18 months prior to index date), females were strongly associated with the occurrence of acute
respiratory infections prior to incident narcolepsy diagnosis. Adjusted ORs for influenza prior to
narcolepsy diagnosis were elevated for males and females for criteria ND1 and ND2 during the
infection periods P3 and P4. However, aORs were only significant for females for ND1, P3 and
ND2, P3.
Overall our findings suggest a greater risk for development of incident narcolepsy occurring
after claims for what would more likely be considered viral respiratory infections. These appeared
to be associated with consistently elevated aORs and many were statistically significant. On the
other hand, the relationship between incident narcolepsy and bacterial respiratory infections
provided inconsistent results. Bacterial pneumonias were associated with elevated aORs, whereas
streptococcal sore throat was associated with varying estimates, even though it occurred in the
second most patients.
During the time period covered in of our study, an increase in narcolepsy risk was linked to
adjuvanted influenza vaccines in various countries.55;65-78;170 However, these types of vaccinations
were not administered in the U.S.20;80 An assessment of over 1.5 million vaccinated patient records
from the U.S. FDA Vaccine Adverse Event Reporting System was conducted for the years 2006
through 2011 after a narcolepsy signal was not detected in the Vaccine Safety Datalink database.80
No cases of narcolepsy were recorded within 6 months of vaccination. Additionally, after the 2010
to 2011 period, only 2 cases were observed. Narcolepsy risk was not associated with the
A(H1N1)pdm09 strain vaccination. It has been suggested that the European AS03-adjuvanted
vaccine may have been able to induce an immune response to brain hypocretin receptors, thus
potentially impacting the regulation of sleep and narcolepsy.171;172 Both the U.S. and Europe
vaccinations used the A(H1N1)pdm09 strain. However, adjuvanted influenza vaccines were not
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administered in the U.S., further implicating the AS03 adjuvant (e.g. used in the Pandemrix
vaccine) in the induction of narcolepsy following vaccination in Europe, rather than the influenza
strain itself. In another U.S.-based study, vaccinated (quadrivalent live-attenuated influenza,
including A/H1N1) patients 2 to 49 years of age from 2013 to 2014 in the Kaiser Permanente
Northern California health plan were compared to unvaccinated patients. Similar incidence rates
of narcolepsy were found between the groups.79 This study occurred following the period of
adjuvant vaccine use and increase of narcolepsy in Europe. However, it helps to illustrate the
difference in risk between adjuvanted and live-attenuated influenza vaccination.
Few studies have been conducted to assess specific infections and their potential to cause
narcolepsy.90;91

The most studied potentially narcolepsy-associated infection appears to be

influenza. However, conflicting results regarding triggering downstream narcolepsy have been
observed.71;74;97-99 Han and colleagues studied narcolepsy patients diagnosed from 1998 to 2010 in
Beijing, China.97

Incidence of narcolepsy was significantly increased following the H1N1

influenza pandemic and was more than 3 times the expected rate of occurrence. This increase was
independent of vaccination, since only 5.6% of incident narcolepsy cases received vaccination and
occurred within 6 months of the pandemic. This same research group assessed the incidence of
childhood narcolepsy in children 2 years after the 2009 H1N1 influenza pandemic.98 Data analyses
from 2011 and 2012 revealed that incident cases of narcolepsy were similar in numbers as those
prior to the 2009 pandemic (5 to 6 times fewer than 2010).
The risk of narcolepsy in children and young adults following influenza infection was
investigated in Norway.71 Residents 3 to 29 years of age were followed from 2008 through 2012.
The risk of narcolepsy within 6 months following influenza infection was elevated (adjusted
HR=3.31, 95% CI 1.01 to 10.79). Non-significant elevated risks were observed 1 year after
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infection (HR=2.36, 95% CI 0.73 to 7.61) and through the end of follow-up after influenza
infection (HR=1.67, 95% CI 0.68 to 4.12). In a case-control study from a U.S.-based sleep center,
63 narcolepsy patients were compared to 63 community control participants regarding possible
environmental factor influences on narcolepsy risk.99 Based on a questionnaire, the only infections
presenting increased risk were influenza within a year of onset (OR=1.79, 95% CI 1.05 to 3.04)
and unexplained fevers (OR=3.89, 95% CI 0.88 to 17.21).
Other researchers have suggested a triggering effect for narcolepsy by certain infections.190
For instance, a case-control study was conducted of the associations of Streptococcus pyogenes
and Helicobacter pylori with development of narcolepsy in 200 cases and 200 controls.95
Streptococcus infection, and not Helicobacter, was associated with narcolepsy. This association
was observed for infections occurring within 3 years of narcolepsy development.
Studies performed in insurance claims databases present some limitations. Our study may be
subject to these typical issues.

For example, the THMCDD does not provide specific

demographics such as race, education, income, height, and weight. Therefore, we were not able
to consider these variables in our logistic regression model or attempt stratification based on them.
However, the dataset did provide the important demographics of gender, geographical region, and
age. With the substantial size of the THMCDD and the rarer occurrence of narcolepsy, this health
claims database, even with its inherent limitations, provides a very beneficial data source for a
case-control study of this type.
Our observations of greater incident narcolepsy cases among women and generally greater
ORs for prior respiratory infections compared to men may possibly be due to the known gender
differences in usage of the U.S. healthcare system. A report of adults 18 to 64 years of age by the
Kaiser Family Foundation found that women had higher proportions of routine clinician
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identification (81% vs 68%), provider visits in the last two years (91% vs 78%), and a reported
condition that required continual monitoring (43% vs 30%).185 Our database of continuous
enrollees contained approximately 52% females and 48% males. Our observed higher proportion
of narcolepsy claims being in females may be due to women utilizing the healthcare system more
regularly than men and actually attempting to have their narcolepsy medically diagnosed.
Additionally, women may be more likely to seek medical attention for respiratory infections.
Thus, it is possible that our study may have artificially decreased the respiratory infection
occurrences among males. However, the much greater proportions in females, compared to males,
that we have observed may actually be ‘real world’. Because of the seriousness of narcolepsy, we
believe it unlikely that the greater reluctance of men to utilize their insurance coverage is enough
to explain the large differences observed. It must be noted, the potential reluctance of males to
seek medical attention for respiratory infections would most likely occur in both the case and
control groups equally. This nondifferential misclassification bias may result in lowering of the
potential association between respiratory infections and development of incident narcolepsy
among males.
Another limitation of our study is the unavailability of medical records to validate the
narcolepsy diagnoses. Additionally, the possibility existed that some MSLT claims may have been
recorded after the diagnosis of narcolepsy was made. These issues could present a substantial
problem to a smaller study. To counter these issues, we assessed incident using two definitions:
ND1 (MSLT claim within 180 days, before or after, of the first narcolepsy claim; a follow-up
narcolepsy claim was also required after the MSLT) and ND1 (MSLT claim within 180 days before
the first narcolepsy claim). We also required the MSLT to be coupled with a PSG, as has been
previously suggested and practiced.35-37;39;40;42-46 Further, to determine if any delays in recording
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of service date substantially affected incident case rate, we reassessed the THMCDD to further
restrict the requirement of PSG claim within 2 days of MSLT. Limiting the allowable service date
of the PSG to within 1 day before the MSLT changed the numbers of incident cases by less than
1%. Therefore the requirement of PSG within 2 days of MSLT was maintained.
We also did not have the availability of medical records to validate infections and their coding.
It is possible that infections may have either not been true cases of the recorded infections, or that
specific infections were missed. However, if this occurred, this is likely to have happened across
all subject categories, among both cases and controls.
Narcolepsy may take years to diagnose. Therefore, signs and symptoms of the conditions
could be missed using this type of study design and length. Regarding study length, we included
index dates from July 1, 2009 through December 31, 2010, and infection look back to January 1,
2008. Evaluation of incident cases may have been affected. Follow-up of more diagnoses would
have been possible with a longer study period. Our two definitions of incidence allowed for
variations in reporting and both required narcolepsy diagnosis after PSG/MSLT. However, there
is still the possibility that some of our incident cases were actually not new cases, due to a
narcolepsy diagnosis before 2008 and the PSG/MSLT noted may have not been the first. These
situations would lead to a possible overestimation of the number of incident cases.
We did not stratify based on cataplexy status. Our previous large health care database study
found that of all incident narcolepsy cases, approximately 20 to 25% had cataplexy.189 The
development of cataplexy may take years after signs of narcolepsy. Therefore, detecting an
accurate infection link to cataplexy status may require many more years of observation.
Even though the THMCDD includes millions of enrollees with many observations, it only
contains information from private-sector health insurers. Medicare and Medicaid data are not
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included. Narcolepsy patients are known to suffer from higher rates of comorbid conditions than
the general population5-10 leading to reduced employment and lost income and reduced
socioeconomic status.1;186-188 The possibility exists that some narcolepsy patients may not be
included in this type of database due to lack of insurance coverage or transfer to Medicare or
Medicaid. Therefore, our study may underestimate incident narcolepsy cases. However, it is
difficult to assess the true impact on OR estimates due to changes in insurance coverage, since
respiratory infection evaluation may suffer from the same migration of health coverage. Since
Medicare is mainly available to the older population, and our study included only patients 65 years
of age and younger, there was most likely little Medicare-related impacts on our assessed
populations. However, it must be considered that disabled patients under the age of 65 who receive
Social Security Disability Insurance (SSDI) would possibly have an impact on our study if
sufficient patients with narcolepsy become disabled or have infections that may have been included
in our study. More likely, the greater impact would have been from the potential Medicaid
population. The preferred next steps would be to conduct a similar study among Medicare and
Medicaid patients.
An additional limitation of the study is the inclusion of only those patients with continuous
enrollment over the entire study period, limiting those who only enroll for short periods of time.
However, the requirement for continuous enrollment is essential for tracking narcolepsy patients
and determining prior respiratory infection status. Although not complete, this restriction helps to
limit the over inclusion of patients.
Our findings suggest an increased risk for incident narcolepsy following recent common viral
respiratory infections. However, this study was unable to rule in or out a risk associated with
bacterial respiratory infections. Future study with at least an additional 3 years of health claims
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data may allow for a more precise estimate of the risk for incident narcolepsy following bacterial
infection, with or without concomitant viral infection.
In conclusion, we observed increased occurrences of acute respiratory infections,
pneumonias, and specifically influenza prior to incident narcolepsy diagnosis, compared to
controls. Generally, these rates appeared higher for females than males and occurred for both
predetermined narcolepsy diagnosis criteria. Additionally, these associations were observed in the
infection assessment periods of 3 to 15 months and 6 to 18 months prior to incident narcolepsy
diagnosis. Increased awareness of the potential narcolepsy trigger by certain infections may aid
in the understanding of the disease. These findings may also have implications in the mechanisms
and causation of other acute onset neurological disorders.
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Table 3.1 – Incident Narcolepsy Criteria and Infection Lookback Time Periods
Incident Narcolepsy Criteria
Abbreviation
Name
Definition
ND1
Narcolepsy Diagnosis Criteria 1
MSLT claim ±180 days of the first narcolepsy claim; a
follow-up diagnosis for narcolepsy must be observed for
cases in which the MSLT is recorded after the first
narcolepsy diagnosis
ND2
Narcolepsy Diagnosis Criteria 2
MSLT claim within 180 days before the first narcolepsy
claim

Abbreviation
P1
P2
P3
P4

Infection Lookback Time Periods
Name
Definition
Lookback Time Period 1
infection occurring within 18 months prior to index date
Lookback Time Period 2
infection occurring 1 year prior to index date
Lookback Time Period 3
infection occurring 3 to 15 months prior to index date
Lookback Time Period 4
infection occurring 6 to 18 months prior to index date
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Table 3.2 – Respiratory Infection Groupings*
Group 1
010.xx
011.xx
012.xx
Group2
022.1

Pulmonary tuberculosis
Other respiratory tuberculosis

032.x
033.x
Group 3
034.x

Diphtheria
Whooping cough

Group 4
112.4
114.0
114.5
115.05
115.15
115.95
121.2
122.1
136.3

Group 5
460.xx to
466.xx
Group 6
480.x
Group 7
481

Primary tuberculosis infection

Pulmonary anthrax

482.x
Group 8
483.x
484.x

Streptococcal sore throat and scarlet fever

485
486
Group 9
487.x

Candidiasis of lung
Primary coccidioidomycosis (pulmonary)
Pulmonary coccidioidomycosis,
unspecified
Infection by Histoplasma capsulatum,
pneumonia
Infection by Histoplasma duboisii,
pneumonia
Histoplasmosis, unspecified, pneumonia
Paragonimiasis
Echinococcus granulosus infection of
lung
Pneumocystosis

488

*Groupings by ICD-9-CM, 2008 to 2010
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Acute respiratory infections

Viral pneumonia
Pneumococcal pneumonia (Streptococcus
pneumoniae pneumonia)
Other bacterial pneumonia
Pneumonia due to other specified organism
Pneumonia in infectious diseases classified
elsewhere
Bronchopneumonia, organism unspecified
Pneumonia, organism unspecified
Influenza
Influenza due to identified avian influenza
virus

Table 3.3 - Demographics and Characteristics of Patients with Narcolepsy and Controls&
Multiple Sleep Latency Test ± 180 Days of First Narcolepsy Diagnosis* (ND1)
Variables
Narcolepsy
Controls
N=1,005
N=40,200
Age$#, years, mean (SD)
37.2 (14.7)
35.5 (18.6)
Range
4-62
0-63
Sex^, n (%)
Female
651 (64.8)
21,120 (52.5)
Male
354 (35.2)
19,080 (47.5)
Geographic Region^, n (%)
Northeast
115 (11.4)
5,483 (13.6)
North Central
401 (39.9)
10,014 (24.9)
South
400 (39.8)
15,902 (39.6)
West
84 (8.4)
8,659 (21.5)
Unknown
5 (0.5)
142 (0.4)
Multiple Sleep Latency Test ≤180 Days Before First Narcolepsy Diagnosis (ND2)
Variables
Narcolepsy
Controls
N=637
N=25,480
Age$@, years, mean (SD)
38.0 (14.7)
36.1 (18.6)
Range
4-62
0-63
Sex^, n (%)
Female
415 (65.2)
13,429 (52.7)
Male
222 (34.9)
12,051 (47.3)
Geographic Region^, n (%)
Northeast
75 (11.8)
3,123 (12.3)
North Central
242 (38.0)
6,321 (24.8)
South
258 (40.5)
10,108 (39.7)
West
58 (9.1)
5,820 (22.8)
Unknown
4 (0.6)
108 (0.4)
&
8,444,517 continuous enrollees from 2008 to 2010. Incident narcolepsy cases diagnosed from July 1, 2009
through December 31, 2010 are included. Controls were matched only on the case diagnosis date (index date).
* a follow-up diagnosis for narcolepsy must be observed for cases in which the multiple sleep latency test is
recorded after the first narcolepsy diagnosis
$
For narcolepsy cases, age was defined as age at diagnosis. For controls, age was defined as age in mid-2009
#
T-test p<0.01
@
T-test p=0.01
^
Chi-square p<0.01
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Table 3.4 – Patients with Multiple Sleep Latency Test ± 180 Days of First Narcolepsy Diagnosis* (ND1)
Compared to Controls, by Prior Respiratory Infections and Infection Period
Infection 18 months prior to index date (P1)

Infection 1 year prior to index date (P2)

Infection
Group

Narcolepsy
N=1,005

Control
N=40,200

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

Narcolepsy
N=1,005

Control
N=40,200

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

1

1

4

Ind#

Ind

0

3

Ind

Ind

2

0

3

Ind

Ind

0

2

Ind

Ind

3

29

1,186

855

0

3

0.97
(0.66, 1.42)
Ind

15

4

0.98
(0.67, 1.42)
Ind

0

2

0.70
(0.42, 1.17)
Ind

0.69
(0.41, 1.17)
Ind

5

455

13,185

10,275

1

35

1.63
(1.43, 1.85)
Ind

365

6

1.70
(1.50, 1.92)
Ind

1

21

1.66
(1.46, 1.89)
Ind

1.60
(1.40, 1.83)
Ind

7

7

138

95

30

709

23

525

9

35

999

2.10
(0.97, 4.51)
1.69
(1.17, 2.46)
1.49
(1.06, 2.12)

5

8

2.04
(0.95, 4.36)
1.71
(1.18, 2.48)
1.42
(1.01, 2.00)

26

727

2.11
(0.86, 5.20)
1.77
(1.16, 2.70)
1.44
(0.97, 2.14)

2.21
(0.89, 5.48)
1.73
(1.13, 2.64)
1.51
(1.01, 2.25)

Infection
Group

Narcolepsy
N=1,005

Control
N=40,200

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

Narcolepsy
N=1,005

Control
N=40,200

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

1

0

2

Ind

Ind

1

2

Ind

Ind

2

0

2

Ind

Ind

0

2

Ind

Ind

3

16

809

821

0

2

0.79
(0.47, 1.30)
Ind

20

4

0.79
(0.48, 1.30)
Ind

0

3

0.97
(0.62, 1.53)
Ind

0.97
(0.61, 1.53)
Ind

5

386

10,327

10,275

1

24

1.73
(1.52, 1.98)
Ind

367

6

1.80
(1.59, 2.05)
Ind

0

27

1.68
(1.47, 1.91)
Ind

1.60
(1.40, 1.83)
Ind

Infection 3 to 15 months prior to index date (P3)

Infection 6 to 18 months prior to index date (P4)

1.59
(0.58, 4.34)
1.60
8
20
518
20
497
(1.02, 2.53)
1.55
9
28
778
26
709
(1.04, 2.31)
* a follow-up diagnosis for narcolepsy must be observed for cases in which the multiple sleep latency test is recorded after the
first narcolepsy diagnosis. Incident narcolepsy cases diagnosed from July 1, 2009 through December 31, 2010 are included.
Controls were matched only on the case diagnosis date (index date).
@ Crude model includes factor for index date
^ model adjusted for sex, geographical region, age, and index date

7

#

4

100

1.60
(0.59, 4.36)
1.56
(0.99, 2.44)
1.45
(0.99, 2.13)

1.65
(0.60, 4.50)
1.51
(0.96, 2.38)
1.53
(1.04, 2.25)

4

100

1.60
(0.59, 4.36)
1.62
(1.03, 2.55)
1.48
(1.00, 2.20)

Ind=Indeterminate estimates due to extremely small cell numbers and/or model adjustment
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Table 3.5 - Patients with Multiple Sleep Latency Test ≤180 Days Before First Narcolepsy Diagnosis* (ND2)
Compared to Controls, by Prior Respiratory Infections and Infection Period
Infection 18 months prior to index date(P1)

Infection 1 year prior to index date (P2)

Infection
Group

Narcolepsy
N=637

Control
N=25,480

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

Narcolepsy
N=637

Control
N=25,480

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

1

0

3

Ind#

Ind

0

2

Ind

Ind

2

0

2

Ind

Ind

0

2

Ind

Ind

3

23

720

1.29
(0.84, 1.97)
Ind

1.31

11

523

Ind

0

2

0.84
(0.46, 1.53)
Ind

0.85
(0.46, 1.57)
Ind

1.77
(1.52, 2.08)
Ind

1.71

233

6,454

Ind

1

11

1.70
(1.44, 2.00)
Ind

1.63
(1.38, 1.93)
Ind

2.81
(1.22, 6.45)
1.68
(1.04, 2.71)
1.57
(1.03, 2.40)

2.87

4

58

14

317

17

426

2.77
(1.00, 7.65)
1.78
(1.04, 3.07)
1.61
(0.99, 2.64)

2.84
(1.02, 7.90)
1.77
(1.03, 3.05)
1.70
(1.03, 2.79)

4

0

2

5

294

8,301

6

1

21

7

6

86

8
9

18
23

434
594

(0.85, 2.02)

(1.45, 2.01)

(1.24, 6.63)

1.68
(1.04, 2.72)

1.67
(1.08, 2.56)

Infection 3 to 15 months prior to index date (P3)

Infection 6 to 18 months prior to index date (P4)

Infection
Group

Narcolepsy
N=637

Control
N=25,480

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

Narcolepsy
N=637

Control
N=25,480

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

1

0

2

Ind

Ind

0

2

Ind

Ind

2

0

1

Ind

Ind

0

1

Ind

Ind

3

11

493

0.89
(0.49, 1.63)
Ind

0.91

16

502

Ind

0

2

1.28
(0.78, 2.12)
Ind

1.29
(0.77, 2.15)
Ind

1.92
(1.64, 2.26)
Ind

1.85

241

6,498

Ind

0

16

1.78
(1.51, 2.09)
Ind

1.71
(1.45, 2.02)
Ind

2.51
(0.91, 6.91)
1.37
(0.75, 2.50)
1.66
(1.04, 2.65)

2.56

4

63

11

314

17

440

2.55
(0.93, 7.03)
1.41
(0.77, 2.59)
1.56
(0.96, 2.56)

2.51
(0.90, 6.96)
1.43
(0.78, 2.62)
1.66
(1.01, 2.72)

4

0

2

5

252

6,473

6

1

14

7

4

64

8
9

11
19

324
463

(0.49, 1.67)

(1.57, 2.19)

(0.92, 7.09)

1.36
(0.74, 2.50)

1.77

(1.10, 2.84)
*Incident narcolepsy cases diagnosed from July 1, 2009 through December 31, 2010 are included. Controls were matched
only on the case diagnosis date (index date).
@ Crude model includes factor for index date
^ model adjusted for sex, geographical region, age, and index date
#

Ind=Indeterminate estimates due to extremely small cell numbers and/or model adjustment
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Table 3.6 – Assessment of More Common Respiratory Infections Reported Prior to Incident Narcolepsy
Diagnosis&, by Narcolepsy Criteria, Infection Period, and Sex
Multiple Sleep Latency Test ± 180 Days of First Narcolepsy Diagnosis* (ND1)
Males
Females
Infection 18 months prior to index date (P1)
Infection
Group

Narcolepy
N=354

Control
N=19,080

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

Narcolepy
N=651

Control
N=21,120

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

3

7

511

675

122

5,434

333

7,751

8

11

319

19

390

9

13

474

0.73
(0.34, 1.58)
1.35
(1.08, 1.69)
1.92
(1.04, 3.55)
1.56
(0.89, 2.76)

22

5

0.73
(0.35, 1.56)
1.32
(1.06, 1.65)
1.89
(1.02, 3.47)
1.50
(0.85, 2.62)

22

525

1.06
(0.69, 1.63)
1.81
(1.55, 2.11)
1.60
(1.00, 2.55)
1.37
(0.89, 2.12)

1.09
(0.70, 1.69)
1.79
(1.53, 2.10)
1.58
(0.99, 2.53)
1.45
(0.94, 2.25)

3

3

374

5

102

4,201

8

6

242

9

9

329

0.81
(0.45, 1.44)
1.68
(1.43, 1.97)
1.98
(1.20, 3.24)
1.40
(0.85, 2.28)

0.82
(0.46, 1.49)
1.66
(1.41, 1.95)
1.92
(1.17, 3.16)
1.48
(0.90, 2.44)

3

3

359

5

97

4,174

8

4

239

9

8

363

3

6

356

5

89

4,146

8

8

224

9

10

327

Infection 1 year prior to index date (P2)
0.43
(0.14, 1.34)
1.43
(1.14, 1.81)
1.34
(0.59, 3.04)
1.49
(0.76, 2.91)

0.42
(0.13, 1.34)
1.47
(1.16, 1.87)
1.35
(0.60, 3.06)
1.56
(0.79, 3.08)

12

481

263

6,074

17

283

17

398

Infection 3 to 15 months prior to index date (P3)
0.45
(0.14, 1.40)
1.35
(1.07, 1.71)
0.90
(0.33, 2.43)
1.19
(0.59, 2.42)

0.44
(0.14, 1.40)
1.37
(1.08, 1.75)
0.91
(0.34, 2.45)
1.25
(0.61, 2.56)

13

450

289

6,153

16

279

20

415

0.94
(0.54, 1.63)
1.94
(1.66, 2.27)
1.88
(1.13, 3.14)
1.58
(1.00, 2.50)

0.96
(0.55, 1.69)
1.93
(1.65, 2.27)
1.83
(1.09, 3.05)
1.67
(1.05, 2.65)

Infection 6 to 18 months prior to index date (P4)
0.91
(0.40, 2.05)
1.21
(0.95, 1.54)
1.95
(0.95, 3.97)
1.67
(0.88, 3.16)

0.92
(0.40, 2.11)
1.23
(0.96, 1.57)
2.01
(0.98, 4.12)
1.72
(0.90, 3.29)

14

465

278

6,129

12

273

16

382

0.98
(0.57, 1.67)
1.82
(1.56, 2.14)
1.43
(0.80, 2.57)
1.37
(0.83, 2.28)

0.99
(0.58, 1.71)
1.81
(1.54, 2.13)
1.41
(0.78, 2.53)
1.46
(0.87, 2.43)

Multiple Sleep Latency Test ≤180 Days Before First Narcolepsy Diagnosis (ND2)
Males
Females
Infection 18 months prior to index date (P1)
Infection
Group

Narcolepy
N=222

Control
N=12,051

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

Narcolepy
N=415

Control
N=13,429

Crude OR@
(95% CI)

Adjusted OR^
(95% CI)

3

3

317

403

74

3,377

220

4,924

8

8

198

10

236

9

9

268

0.50
(0.16, 1.59)
1.30
(0.97, 1.74)
2.33
(1.13, 4.80)
1.94
(0.97, 3.86)

20

5

0.51
(0.16, 1.60)
1.29
(0.97, 1.71)
2.23
(1.09, 4.58)
1.84
(0.94, 3.63)

14

326

1.64
(1.03, 2.60)
1.95
(1.60, 2.37)
1.38
(0.73, 2.63)
1.41
(0.82, 2.43)

1.74
(1.08, 2.80)
1.96
(1.61, 2.39)
1.37
(0.72, 2.60)
1.53
(0.88, 2.65)

3

1

238

1.14
(0.60, 2.16)

1.20
(0.63, 2.29)

Infection 1 year prior to index date (P2)
0.23
(0.03, 1.61)

0.22
(0.03, 1.60)

93

10

285

Table 3.6 – Assessment of More Common Respiratory Infections Reported Prior to Incident Narcolepsy
Diagnosis&, by Narcolepsy Criteria, Infection Period, and Sex - continued
5

60

2,616

1.34
(0.99, 1.81)
1.51
(0.55, 4.10)
1.82
(0.80, 4.14)

1.36
(1.00, 1.84)
1.56
(0.57, 4.26)
1.90
(0.82, 4.37)

173

3,838

8

4

145

10

172

9

6

181

11

245

3

0

225

Ind#

Ind

11

268

5

59

2,596

3,877

3

149

8

175

9

6

206

1.34
(0.98, 1.82)
1.16
(0.36, 3.66)
1.65
(0.72, 3.81)

193

8

1.32
(0.98, 1.78)
1.09
(0.35, 3.45)
1.57
(0.69, 3.58)

13

257

3

2

218

1.78
(1.46, 2.18)
1.91
(1.00, 3.64)
1.47
(0.80, 2.71)

1.78
(1.46, 2.18)
1.88
(0.98, 3.59)
1.61
(0.86, 2.98)

Infection 3 to 15 months prior to index date (P3)
1.34
(0.73, 2.47)
2.14
(1.76, 2.61)
1.49
(0.73, 3.05)
1.68
(0.95, 2.96)

1.41
(0.76, 2.62)
2.16
(1.77, 2.63)
1.46
(0.71, 2.99)
1.82
(1.02, 3.23)

Infection 6 to 18 months prior to index date (P4)
0.49
0.49
14
284
1.62
1.70
(0.12, 1.99)
(0.12, 2.01)
(0.94, 2.80)
(0.97, 2.96)
5
55
2,586
1.20
1.21
186
3,912
1.98
2.00
(0.89, 1.64)
(0.88, 1.66)
(1.62, 2.41)
(1.63, 2.44)
8
6
142
2.32
2.51
5
172
0.94
0.94
(1.01, 5.31)
(1.09, 5.77)
(0.39, 2.31)
(0.38, 2.29)
9
7
194
1.96
2.06
10
246
1.34
1.46
(0.91, 4.22)
(0.95, 4.49)
(0.71, 2.54)
(0.77, 2.79)
&Incident narcolepsy cases diagnosed from July 1, 2009 through December 31, 2010 are included. Controls were matched
only on the case diagnosis date (index date).
* a follow-up diagnosis for narcolepsy must be observed for cases in which the multiple sleep latency test is recorded after the
first narcolepsy diagnosis.
@ Crude model includes factor for index date
^ model adjusted for geographical region, age, and index date
#

Ind=Indeterminate estimates due to extremely small cell numbers and/or model adjustment
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CHAPTER FOUR
CONCLUSIONS AND RECOMMENDATIONS
Key Findings and Implications
Our goals were to enhance the knowledge regarding the epidemiology and possible respiratory
infection triggers of narcolepsy. The primary objective was to assess whether patients diagnosed
with incident narcolepsy were more likely to have been recently diagnosed with prior respiratory
infections, compared to controls. Using this large U.S. health care claims database with almost
8.5 million enrollees with continuous coverage from 2008 to 2010, we found prevalence and
incidence proportions that were generally greater than most other published estimates. Prevalence
and incidence for narcolepsy without cataplexy were actually several times greater than narcolepsy
with cataplexy, an unexpected finding. Even when using liberal, moderate, and conservative
criteria to define incident narcolepsy, these findings of greater proportions for narcolepsy without
cataplexy remained. Prevalence and incidence were approximately 50% greater for females
compared to males across most age groups. Prevalence was highest among the 21-30 age group,
with incidence highest among enrollees in their early 20s and late teens. The North Central U.S.
had the highest prevalence and incidence, while the West was the lowest.
In the case-control study, we found that patients with incident narcolepsy were more likely to
experience prior acute respiratory infections, other pneumonias (bronchopneumonia, etc.) and
influenzas compared to control patients matched only on the date of the cases’ narcolepsy
diagnosis (index date). This finding was generally consistent across various pre-index time periods
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and for the two employed incident narcolepsy criteria. The respiratory infection and narcolepsy
risk was approximately 50% greater among females than males.
Our findings suggest that the prevalence and incidence of narcolepsy are higher than most
previous assumptions. Additionally, the observations of much greater proportions for females and
patients in the North Central region of the U.S. are quite novel. Finally, it appears that some
respiratory infections may have a strong impact on narcolepsy development. We found a greater
occurring after claims for what would more likely be considered viral respiratory infections. The
relationship between incident narcolepsy and bacterial respiratory infections provided inconsistent
results. These findings suggest that 1.) there may be different influences on the mechanism and
development of narcolepsy between males and females, 2.) regionally associated environmental
exposures or diagnostic practices may contribute to narcolepsy development and identification,
and 3.) respiratory infections may play a role in enhancing autoimmune and other biological
responses responsible for triggering narcolepsy.
Significance of the Dissertation Research
As discussed earlier, even though pharmaceutical products have shown promise in treating
its symptoms, narcolepsy is an incurable, chronic neurological disorder.1-4

These patients

experience various psychiatric and physical comorbid diseases and mortality at an increased rate
compared to the general population.5-10 An approximate doubling of various annual healthcare
related facility visits, transactions, and costs for these patients adds an excessive burden on them,
their families, and the public health system.11 The mechanism associated with the development of
narcolepsy and the destruction of hypocretin neurons is not clear.1 Two of the more noted
hypotheses for this pathology are autoimmune and infection based triggers in allele carrier
patients.22;23 These have especially gained traction after narcolepsy increases were observed
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following influenza vaccinations and possible influenza and streptococcal infections.23 Therefore,
this dissertation is very relevant.
The understanding of the epidemiology of the condition and factors that may impact the
disease development will aid immensely in early detection and treatment of vulnerable
subpopulations and possibly help in researching of mechanistic pathways and prevention
strategies. This dissertation helps to fill in knowledge gaps that exist. Additionally, our findings
may contribute to the understanding of mechanisms of causation of other acute onset neurological
disorders and general methods of assessing these factors.
Recommendations for Future Research
Our assessments obviously have limitations. We did not evaluate impacts of drugs prior
to narcolepsy diagnosis and did not see these types of studies in the published literature. Future
research into possible pharmaceutical impacts on incident narcolepsy are warranted. Some
narcolepsy patients may not have been included in this type of database due to lack of insurance
coverage or transfer to Medicare or Medicaid. It is difficult to assess the true impact on our
prevalence and incidence estimates. Also, respiratory infection evaluation may suffer from the
same migration of health coverage. The preferred next steps would be to conduct similar studies
among Medicare and Medicaid patients. We observed significant differences in narcolepsy
diagnosis according to geographical region. This may be a product of coding practices or the result
of some environmental exposures.

An investigation into the prescribing practices and

corresponding diagnosing may help in understanding if these differences may be due to what
insurances are willing to cover, which in turn promotes intentional miscoding (e.g. regional
insurance plan may cover a prescription for a drug to treat narcolepsy/cataplexy and not another
condition for which it has been found effective, thus influencing prescribers to code the patient as
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having narcolepsy). With respect to geographical region, further studies into environmental
exposures (e.g. sunlight, vitamin D, other infections, toxic substances, diet) are warranted.
Finally, we found an increased risk for incident narcolepsy following recent common viral
respiratory infections. However, this study was unable to rule in or out a risk associated with
bacterial respiratory infections. Future study with at least an additional 3 years of health claims
data may allow for a more precise estimate of the risk for incident narcolepsy following bacterial
infection, with or without concomitant viral infection.
Conclusion
We observed higher prevalence and incidence of narcolepsy compared to most previous
studies. Women were associated with approximately 50% increased proportions compared to men.
We also found that the greatest prevalence and incidence of narcolepsy occurred in patients in their
early 20s, and those residing in the North Central region of the U.S. Perhaps most striking was
the observation of much greater proportions of narcolepsy without cataplexy compared to
narcolepsy with cataplexy. In the case-control assessment, we found increased occurrences of
acute respiratory infections, pneumonias, and influenza prior to incident narcolepsy diagnosis,
compared to controls. Generally, these rates appeared higher for females than males and occurred
for both narcolepsy diagnosis criteria.

Increased awareness and early notification among

healthcare providers for signs and symptoms of narcolepsy is critical in helping this population of
patients manage this burdensome condition. Also, the identification of potential narcolepsy
triggers by certain infections may aid in the understanding of the disease. These findings may
have implications in the understanding of mechanisms and causation of other acute onset
neurological disorders. Further research is warranted.
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APPENDIX A:
CREATION FLOW OF THE DISSERTATION DATABASES
Received 11
DVDs,
~47 GB

(Years 2008 to 2010) – 104 datasets representing 8 categories: Annual Enrollment,
Outpatient Pharmaceutical Claims, Facility Header, Inpatient Admissions,
Outpatient Services, Aggregate Populations, Inpatient Services, Enrollment Details

All individual Year datasets stacked
separately by 8 overall categories

Visually inspected and checked
datasets against the data dictionary
and Data Quality Reports supplied by
Truven

Annual
Enrollment
dataset

All patient specific datasets with visit variables,
including ICD-9-CM codes, CPT codes, dates,
demographics, etc.

Outpatient services,
flag all MSLT, PSG,
NARC

Inpatient
services, flag all
MSLT, PSG,
and NARC
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Inpatient
admissions, flag
all MSLT, and
NARC

Facility header,
flag all MSLT,
PSG, NARC

Dataset created of patients with
continuous enrollment, from 2008
to 2010, from Annual Enrollment
dataset

Dataset of cases and
controls (without
narcolepsy),
matched on incident
narcolepsy lookback
date (index date),
ratio 1:40

Outpatient
services, flag
all respiratory
infections,
remove nonrespiratory
infection
observations,
making sure
each enrollee
has at least one
observation
regardless of
infection status

Dataset of cases and
controls with index
date July 1, 2009 and
later

Outpatient services, Inpatient
Services, Inpatient admissions,
Facility header datasets
stacked

Merge stacked patient
information datasets with
Annual Enrollment
continuous patients to
determine Incidence and
Prevalence

Inpatient
services, flag all
respiratory
infections,
remove nonrespiratory
infection
observations,
making sure
each enrollee
has at least one
observation
regardless of
infection status

Inpatient
admissions, flag
all respiratory
infections,
remove nonrespiratory
infection
observations,
making sure
each enrollee
has at least one
observation
regardless of
infection status

Merged dataset of
study subjects and
observations, remove
infections occurring
post-index date

Stack patient datasets
containing respiratory
infection flags,
narcolepsy also
flagged

Final
demographics

Merged dataset for respiratory infectionsnarcolepsy case-control study.
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Facility header,
flag all
respiratory
infections,
remove nonrespiratory
infection
observations,
making sure
each enrollee
has at least one
observation
regardless of
infection status
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